{"docstore/metadata": {"379a7942-d426-4d60-a7cd-d4ce1dafcd41": {"doc_hash": "6985aae14069a604a8a243f9652a7fb4624ecdfb29111544e27b070415d22dcd"}, "b459346f-b701-49a9-ba4c-becbd4f6eef8": {"doc_hash": "ef4d61a32bc24dbdfd6f2a8b13c5a1901aaaf84f16153da370be10a870b3bf84"}, "2b70ecd1-b2bd-4753-b17c-f1426aca769d": {"doc_hash": "07eeebd80ac7237292031e2bbf9bb211491f5c2ae38c08ee993f5ebc33856421"}, "a189ad72-2a7e-43a4-9ab0-2310630984ab": {"doc_hash": "a0630ae607f91f75360b70543422a289cd1818c014877e528f5dba6d11afb3db"}, "8a1c836b-d65d-440a-8f99-22f1348c46b8": {"doc_hash": "4de6a61d3906cb23d20db5ea8091cd9e2e39bd97754d9d497309086120dab8a5"}, "52b88f37-a79a-4ab6-84ba-e169a631b807": {"doc_hash": "2d67d85ddbbeff88f3c7c5a892d21eaed5e3ad3a36b7dc171d6586b128435d70"}, "1e0ce963-25d3-4f79-8244-c2d6ac4b0195": {"doc_hash": "d20b8486923297ba699e36c282d4d9a0822fb21f162c41ec47d27f349596716b"}, "eb101c39-4be2-463b-bc2c-43fddb5d4189": {"doc_hash": "a3de013655e8b8d353ff2d103229bf417198ae0efdb8b5fdb59743205cbc60fe"}, "f7b640a4-06ea-4603-a995-3e1d426bdb29": {"doc_hash": "62b4cb49c8d163c652c70e93d3798a754ef64c6c53aeafedcd0b73a459daeec0"}, "525d253d-709c-4846-85ed-050168e9b353": {"doc_hash": "7d30d8af654cd292a28d587b0a881163dc122757507a7c6adf2b1f3dd52ed422"}, "b88ac031-8b9a-40ee-8b4f-d46457879876": {"doc_hash": "f746e9b9a3cf5c29ae4ed7d135028b6fb7bd9d0286eca83cbebd3c804b4982f5"}, "cc6a8cb5-a714-4c19-854d-448b4e7facc1": {"doc_hash": "c3eb931dc9826e01e04cd32806719c8d47a61e71ddc0a3396830c4011cdae0e0"}, "f78d6af1-a210-4614-8709-dadee648219e": {"doc_hash": "b8792b0ff66894a43af49d8ecb1ba9b0359c1efa2955ce629c6126908efabf2b"}, "68f5f365-9515-440f-99d0-d0a7d7f744f4": {"doc_hash": "6ff8a77f1dc42daf88d71f361f05dac644a3caa1bfb328036db2e76a8bc3e486"}, "75f276b1-dc73-448d-b3df-f2949ebae042": {"doc_hash": "eee08280146e410a372bdbb5701db8087bd9481f93d699f4066a22a0ea44bc7e"}, "9ebcde90-cd9f-4577-b66e-0492708e0483": {"doc_hash": "9333fa05f8168ba21743c164403efe6424d0c1f1bd5555dbe8f1205ff3ddc0b5"}, "10c759b9-62c2-403f-b566-b50f9b521dd0": {"doc_hash": "2af7a040187105b9c4f8b0f9454fe7a021f84da3a66a614999a56020a7f1c789"}, "1b520a3e-d95e-473e-bd63-7e54520282b1": {"doc_hash": "00b225c46425f1a4be98bd02ad3f261ff63a1c6461b495f0012c9ba891cbe7a1"}, "c2bb20df-19eb-479c-8207-5232fd6face1": {"doc_hash": "4c8057c395f1a6b506287e882db6c08736800d301a8f6a04d8136869761f65bc"}, "ee375edc-6a5b-44ba-9063-9fadb3fb3854": {"doc_hash": "b46651a8fea1f75ed6b59a7fcf9f6eecc27a5ec07b76559a0f4f4cb7c2df85ff"}, "32a92ec0-51a7-4325-afbf-7964259752a1": {"doc_hash": "d6d77508e30620273f43ec5e20a9d5fc8b599eef213ac49301dd14f48a8ad66d"}, "f4c367a5-8e03-4981-8d10-e577efa17c6d": {"doc_hash": "1d5580db516fb6c656495e2db5c715dd260bb80514d39412107d3141874c71e1"}, "8f65c141-4a20-4b4d-b945-bfe013e121f2": {"doc_hash": "24c8544948a08e243a50d34bdbe78cf5ff272d2dc35d9b13a70a8be8517b95dc"}, "07d95561-d14c-499b-966d-0d03d75e7d29": {"doc_hash": "ad0854c0b8a2b51083fb8c999ec6d02e462d5d64650bfcf7cb4221b0ba52eb8c"}, "85c9ae0e-3931-457f-9c7c-3e9a99677b3f": {"doc_hash": "e887813869b56404031b68653bf55382c57a06bd4a91c8c05f72df8477305e45"}, "86a20e20-d169-455e-9851-3c0fd1e349f7": {"doc_hash": "2b5fe89437f69a6d5a80b8deb8789731350beb5ba72485d258342672761e1893"}, "33edf4a4-5010-4d67-a387-7db9d38877c0": {"doc_hash": "697e19aeea1239df4ebc0f0ca8d53d4d1b36598022d7f825e4a9c6c293fa0b5c"}, "51184805-c391-407c-b8ab-43ef952e090e": {"doc_hash": "a8bb2f4d7d024dce9d7bda12b67c025afd9b63e77882a7c22a0dba19aa70ef56"}, "515b3860-179f-4d79-aa5f-c7af37b77a69": {"doc_hash": "0eec18d411a4b675038b6978e0c8b2652e35d4c1243ae681eea427b75a267b45"}, "825bc117-ff0a-42be-9d9f-35c8bbac21ba": {"doc_hash": "37f8ee968585b3669444303e746a502f82aff6d0958148cf6dff8fda0c69ac00"}, "07754aab-2daf-46b0-9cfb-75a40022faf2": {"doc_hash": "38d8c3e53b1fd2b82290f7de62bf44159e3bbeebf5f587f29ec7c77db552ae05"}, "480f028e-4b50-4e77-9fab-3ca65be81ffe": {"doc_hash": "d9e5304c87e2faf71ed14f849c6f743bc6a893bf9c9bc4222085fd3a24fc2267"}, "f986cd49-070b-4d42-ac9b-cd894a9d834e": {"doc_hash": "7b9ec45056603b95ee493183159d1255302a0fe690e71a00e69434f754e6a2a9"}, "ddc54b96-3ab6-4f99-8e78-a6437c6d1877": {"doc_hash": "8f6ca984ad937f6864101cfa9ebc65c2b9bd7c42385fc55f0c742a7f21e9f2db"}, "09a23a89-d6e1-4b37-9770-96bbe87560b8": {"doc_hash": "8ed8b399e332a627c77e064d3560935e93140a2139fd67fe76fbe492efed57dd"}, "bab6e1af-7013-497b-984a-62fbc119b94b": {"doc_hash": "e807e3ce7f61074df0e896efa040484771c7da09fa6522fe23b90ab3e404e0cc"}, "fad18478-0f39-4f3c-a26c-6e7417c6bc30": {"doc_hash": "45577b3811caa5b892d38c7a2cd9eaec1231cd86c3c5ccb35a72443bf2a70ca9"}, "bca5d914-8363-4775-aa79-0dbcf482ef98": {"doc_hash": "16b6cafec4a65ba8bb057510bc036b959b14296729f5efaf9e6baed6ff3dd142"}, "0718ecd1-aaa4-4496-b175-b691c8ec8833": {"doc_hash": "ccb0b9709e0402a96e94117eea359f72708368848ba370c784e770fa7161eefd"}, "0a8126e6-ef15-4069-9014-9377e77bd8db": {"doc_hash": "49c557208e90e8debc0b40b0dd9ec6e980f1f3071fa1f4a014783b76ddc7772d"}, "8e6ff787-6761-4b6a-b47e-a803bb22633f": {"doc_hash": "7d30d8af654cd292a28d587b0a881163dc122757507a7c6adf2b1f3dd52ed422"}, "a2fb9a64-965e-44fc-b82c-f8bb58aed32c": {"doc_hash": "bb11de061acc93bd5ee3a4de8c3e86dfad35219cc09e145861b10cc218e7b320"}, "626fd3ce-52cf-46df-bd55-c7979f3387b5": {"doc_hash": "972d1e2628584835aa42735c64eae9f93f9bdb6ab0a95c631a95b9d343ede40d"}, "69c3357b-940f-4cf6-98b1-0ffc12680b76": {"doc_hash": "eb29027318d16cc63317c63a3a8d4a634efdb9eaffedea310666ab25c94f9ab0"}, "d00cd52c-48dc-458b-9461-63bed191d1e9": {"doc_hash": "2232b6df5d425dad2519eb811a3bcc706a7771f6168a237855ec117840ea5b40"}, "fb58b84b-0bc3-47a0-b8be-951afaf2f4d6": {"doc_hash": "2f01efb1793fdd7312a26f29be41155858a6239dfbba2a80117b2b60ce91a7f9"}, "f76c1a1d-6034-4baa-9a23-b67b5202f40e": {"doc_hash": "17385c6ff3fad6dc669e9faa4a1fb92ea2894afa4cdfae9e3d227da14736ba8a"}, "3efc6a40-a67d-4302-8a96-b5b6fc28415b": {"doc_hash": "0156db1beb742138f7e31c96bafe9c68e55a587948192f1d44d021130ef4f097"}, "64402d25-895d-45d9-9695-c3c7ae6162fe": {"doc_hash": "24db812e12c54e8be49f2f524688fd5f267d87d41ef5e0d3e53420008d9a853a"}, "3ce22e43-adb2-43cb-bd8a-67ffc57caefc": {"doc_hash": "ee2ea7dc33a7dc09a37cb1fe85453cbb1811737878d15cebdc0e3bde89e48d75"}, "ce3cb6ab-8fbe-4b47-99d2-8c5ba4e19a7d": {"doc_hash": "a92c9a3d1b0c5d63a5c7929ef490531f733f454ad96ba078eb103af00795da8e"}, "5f30f38c-7a63-4baf-89f3-6b75728d8ea4": {"doc_hash": "49c557208e90e8debc0b40b0dd9ec6e980f1f3071fa1f4a014783b76ddc7772d"}, "92e960f6-092d-479b-aa01-55aec4130a70": {"doc_hash": "5cf459d41a017dc6c258e70e03b3dcc873d8c90fa0622b60dc67f8503484445e"}, "a8c94450-1b41-4e27-b5da-497cc15d07fc": {"doc_hash": "7ebb13fd7626437ac5a59b67304f0bed5a70b7600482cc2f03fd32dd866d64d4"}, "f6ae0ff4-9c4f-4870-952a-efb73935703d": {"doc_hash": "d9e5304c87e2faf71ed14f849c6f743bc6a893bf9c9bc4222085fd3a24fc2267"}, "9b6e527d-f83b-4095-848f-44ea0803e244": {"doc_hash": "2f01efb1793fdd7312a26f29be41155858a6239dfbba2a80117b2b60ce91a7f9"}, "575791d3-021b-4569-9de9-d1b0afdcdf0d": {"doc_hash": "17385c6ff3fad6dc669e9faa4a1fb92ea2894afa4cdfae9e3d227da14736ba8a"}, "af5a7a84-a0ba-4ac0-8ea8-36502e81ccbe": {"doc_hash": "49c557208e90e8debc0b40b0dd9ec6e980f1f3071fa1f4a014783b76ddc7772d"}, "045b78b1-9c84-4a29-8bf7-64c94e60e9be": {"doc_hash": "38d8c3e53b1fd2b82290f7de62bf44159e3bbeebf5f587f29ec7c77db552ae05"}, "3c86e01d-19ee-4dde-bd3d-07fda3d2da7a": {"doc_hash": "3a73eb66788bbf4516e6523f790911a85993a909eb1e6d1ce8099ebd316be55f"}, "7570211d-85c8-49da-99e1-dc3f037d83f4": {"doc_hash": "f4ed3a8f8784414a5cebcd82bcc1241300decdf95ad9b20a3165fb4da4367def"}, "6bfa7dcd-dc94-4b23-9257-141945c3cb48": {"doc_hash": "d90aed061e70c1fbca7992276041e97ec4b583c93ceb5b97f40dc9f80e017b23"}, "463d7c25-6d92-4c5c-8eee-9cc27fb0bd6e": {"doc_hash": "3a73eb66788bbf4516e6523f790911a85993a909eb1e6d1ce8099ebd316be55f"}, "a6692b3f-56dd-4ef4-844c-31bac5698b03": {"doc_hash": "f4ed3a8f8784414a5cebcd82bcc1241300decdf95ad9b20a3165fb4da4367def"}, "5ccfc505-d8c2-43ad-817e-e36d7300b179": {"doc_hash": "d90aed061e70c1fbca7992276041e97ec4b583c93ceb5b97f40dc9f80e017b23"}, "9a4862c0-2c36-41df-8ad4-981878441600": {"doc_hash": "2faa334d2dbd39f7a01f01c1388864e6005a88d0862d6512cd269971e5dc42a8"}, "0c072d0a-6a98-4e1a-a7cd-79b9c71589ad": {"doc_hash": "f51f31a02bfe62caa04890d9b19796c550510ac2e243cbbf97d02ee614e86c80"}, "6fd149d8-f196-4892-abae-fe698f01916a": {"doc_hash": "6d3a2f5ab27c6e3b26707ebae0723db6b97ac39c1456e81c280578fadfece70f"}, "ed943ff1-0464-4398-bf7a-0d8fbbeca0d3": {"doc_hash": "2faa334d2dbd39f7a01f01c1388864e6005a88d0862d6512cd269971e5dc42a8"}, "c2a9410d-1021-4b1d-8e37-76dccb721b03": {"doc_hash": "f59e96987b3fd110082c56e77677326392bb8d050c8d9d08009c633e373a8c8c"}, "c7c7a898-be6e-4468-8923-0f77a490f21b": {"doc_hash": "67bea5e767e0192a3f33200493f34539c6bc8918aa62e8d4988092c65e43971c"}, "e6bdfe42-9113-47df-b54e-67412f7c081b": {"doc_hash": "f54d99c7ffd6bca5f56d97411ceb8c0a5ecb1813f0a0ad307581ddb997e38758"}, "d7e62501-a8c4-4a6e-a73e-25a3c43e674e": {"doc_hash": "b2d7c155574ee8296b72d67083803c6ea8039dfc34e76a89a903bd9fb8604763"}, "d7bcf9d5-4a1a-4699-ba6c-bee2cdc9f4f2": {"doc_hash": "89e209c523efcdd081365d6f589ad70ee0dd9c2b771133ed74b2bdcec4bc6c40"}, "b6293498-5a80-4cd9-867a-a96a606120c7": {"doc_hash": "ab4ac652195b9a0ddc6d5bce4f4220951ac5c40bc9545ddff84f5bc729767aed"}, "86c69809-b181-46bf-97fb-cd56e19ce40a": {"doc_hash": "7fd708ed3ae22a9072a3b145dd9df237ce375a212cf2aa84a865007c904f4782"}, "ffc793a0-da1d-4e88-a2a1-51691fcf509a": {"doc_hash": "70064e5ad08c9962bcf4b6dbadbf1b9cf173f7a7da10541487b1ad08d29c1c4b"}, "463571c9-bab0-44a7-a4c9-9782851b527a": {"doc_hash": "1b56b105e3625992e5b7814756cd9b6e22169693e4de4de7ecc850e9b5e33938"}, "63660035-afd4-49a0-9037-19a6544bd45e": {"doc_hash": "d835e78b6a9a3a278d28af811f73e8f2553784d47485d3dd5319830960a1cbd8"}, "0a8d410b-a401-4b20-9834-167ece82cebc": {"doc_hash": "b8cacdc4774cfe4cdccabf05a42e91036cdb42434591c4138c85d4bccf1caf5f"}, "4afe26dd-d1bc-4481-9832-6cc606f78391": {"doc_hash": "66fb98805b15b3eb1469c44045b1de10aadb80ebd9241bc0b9c454b49ba4f298"}, "80fca3a0-4dfa-411f-bbb6-cd2f625818fb": {"doc_hash": "d9e5304c87e2faf71ed14f849c6f743bc6a893bf9c9bc4222085fd3a24fc2267"}, "a0272232-94c8-4747-a942-8e0ee6b62ccc": {"doc_hash": "07512fe53c7d176a7e944b0d329bd228af68643beffe7f684a95926c1ff5a644"}, "aed126ba-a4fa-4b2c-b857-3ceed2e5e5ec": {"doc_hash": "742d9321eed05657d65f3a2d1b185d320063b3f39c9d67bcfdc38962040d41af"}, "c38c3e6f-110e-41f5-98df-fdf5a2d1eac5": {"doc_hash": "768f5da7c9291650cda1c8eb1b00f6f9b64de009d5d504340b66c6287cb37778"}, "92371eb7-be2c-4107-b52d-c3f5a2366918": {"doc_hash": "f69d08c30dfbe3099916e59f6351bdbaa86d8936e54510dd03f382295db72022"}, "f18e879a-48ae-44ce-a2af-543a3b26af23": {"doc_hash": "288c26c9458adf8dd9879c160a5060f7119112c069af245be649ea01f9e88612"}, "46bf9d8e-8bb7-46de-bafb-d855f44a4096": {"doc_hash": "0913cab85f7312bf6c6f62139449b41e2554fe5f6eb45262136bdad68244c8da"}, "e4e387fe-96f4-49ce-9a6e-9f9e5fc4e0e1": {"doc_hash": "15697f20de9febc64a0a96d5a857363e2ab6a0c864f3452617e6a280356df496"}, "c3239938-f567-4119-8c83-bd0950043528": {"doc_hash": "d78b8c42cfbd2b612b4f5a090399fc6ff0d7755bd46eb9c61b96c6c22bf7863d"}, "d199bceb-69c6-40f1-8c0c-f38cedd54f65": {"doc_hash": "84191d2d7c13147b66f48224d18799459ed95cae320bc1370f55f384bdac4629"}, "1f8a1b4a-bb8e-4a09-a7d6-c24fb34821e1": {"doc_hash": "7cd2e1156a84d047fb438d3372115e6c3ad70712ebb6ced0f0b16bd442ee4707", "ref_doc_id": "379a7942-d426-4d60-a7cd-d4ce1dafcd41"}, "566ff003-e9c6-421e-ab87-7b01605105d7": {"doc_hash": "543fd17ee2fab62c46c78603435e390523e07990f73358bd686e1b483b3cb024", "ref_doc_id": "b459346f-b701-49a9-ba4c-becbd4f6eef8"}, "7d3e29da-89a0-4112-84a9-6c2ed1139717": {"doc_hash": "88a2d61c58f536ef4e77eda6d74d6b3355ae7f1a9384e812e2f71172aa73fe5a", "ref_doc_id": "2b70ecd1-b2bd-4753-b17c-f1426aca769d"}, "4a3ad329-9f70-4f8a-83cf-befe036a4a46": {"doc_hash": "2a37bd5c8f7910c3bcc769b453f54d3a4ebfa9ef3f55db1c2db39f463abf24bb", "ref_doc_id": "a189ad72-2a7e-43a4-9ab0-2310630984ab"}, "5b962085-5130-4e8d-a4b0-140ed4db2936": {"doc_hash": "ab4ace7e520bfbd5a246710bed946f308cb35b5a26d393eba1b8ffe3914a0848", "ref_doc_id": "8a1c836b-d65d-440a-8f99-22f1348c46b8"}, "ad6d9332-1f2f-44fd-8d75-ac976234fb18": {"doc_hash": "01dbf039b058ef0321f811a82ebacb0c9eb6f9d3b601d785001a45f9f94d44e6", "ref_doc_id": "52b88f37-a79a-4ab6-84ba-e169a631b807"}, "9c122296-d245-4c54-a42b-82163b1b8b93": {"doc_hash": "0a096fb81d828d5b9a5339b7d60f82e6fc282d124f1ee6f174cf3364aba8b816", "ref_doc_id": "1e0ce963-25d3-4f79-8244-c2d6ac4b0195"}, "9935b7e9-6b2a-4f59-b82f-6aab5d775c93": {"doc_hash": "ff7a26c5991134bfae7e431fee188ae673cbb3405ef270f86ec993328d764280", "ref_doc_id": "eb101c39-4be2-463b-bc2c-43fddb5d4189"}, "d0da3769-8197-454d-b6a3-1603946c9630": {"doc_hash": "4b213abf3a94a50b1d6047241bba02c20523788e2c35b7042985fd54a08bd132", "ref_doc_id": "f7b640a4-06ea-4603-a995-3e1d426bdb29"}, "2db3b3fa-1725-46e9-9363-ff0184a237f9": {"doc_hash": "263d9a1004b8ce973a20eb0e1f61fbe436c8384e3958682d82efce485e6ee14b", "ref_doc_id": "525d253d-709c-4846-85ed-050168e9b353"}, "58479ebc-7ccc-4212-a2b7-4e3dc92639e8": {"doc_hash": "e3e124ac84efbcdc95747e1e195119da85506f372fcdd884f1f7cf6fe2bb83c6", "ref_doc_id": "b88ac031-8b9a-40ee-8b4f-d46457879876"}, "ff389915-24b9-4cc0-b702-9350b6bb9a79": {"doc_hash": "4afbf074467df95c75e71ffa620720578093d381e4b215d53edf0cebfab84579", "ref_doc_id": "cc6a8cb5-a714-4c19-854d-448b4e7facc1"}, "5149fba1-44cb-462e-bca7-d2d8d7c480e5": {"doc_hash": "a0e793e1d2bb5a4b2523286ae6e359abc410273960fc80ca8a18a71413ea9936", "ref_doc_id": "f78d6af1-a210-4614-8709-dadee648219e"}, "d18b1e00-33ad-4c77-bd3e-9f68b5e8e5a8": {"doc_hash": "68f84681303c474c09ec00c44acfb5cf286604757b50c98f79f504b30daa6cc2", "ref_doc_id": "68f5f365-9515-440f-99d0-d0a7d7f744f4"}, "a5059593-19bf-440d-bc3e-c4302034d845": {"doc_hash": "eaa3f6beb928b8731ff522f90d0069edf95662ae263c946acee5f6172fdc1358", "ref_doc_id": "75f276b1-dc73-448d-b3df-f2949ebae042"}, "e4b2144b-4676-477c-9fcf-3f16ca35a752": {"doc_hash": "4d1c4bbcb61ed173ea3475054f29306bea69b9bad3e8b6454c49d5bc92ee14fc", "ref_doc_id": "9ebcde90-cd9f-4577-b66e-0492708e0483"}, "a20600b6-e2cf-4dcc-94b1-41b1f8d0a1ae": {"doc_hash": "ef0e363084e5622a15463d396589640fab68d1f3a52f6c5d05cb46a04294d7db", "ref_doc_id": "10c759b9-62c2-403f-b566-b50f9b521dd0"}, "fff52cff-78ea-4507-b56e-49e61f916d47": {"doc_hash": "fbc0e9c1515c4e0bca7da7cbe59b992623a82e6b5c1f651f68e25ef0341439e0", "ref_doc_id": "1b520a3e-d95e-473e-bd63-7e54520282b1"}, "38d5ffb7-2cb5-4f2d-a464-a530361e5bbb": {"doc_hash": "a842f316aec29768960e2b914bc7819cd26b562668321ebf9709b02bed2ee694", "ref_doc_id": "c2bb20df-19eb-479c-8207-5232fd6face1"}, "8c25c87c-a435-4f15-873e-4d44247c4968": {"doc_hash": "afb6406a93ff66891225b549c6f135f4cf4f7da600d0896d6e5b5366fccb7506", "ref_doc_id": "ee375edc-6a5b-44ba-9063-9fadb3fb3854"}, "2d43d55d-ca09-41fc-bb78-8f71dd775f55": {"doc_hash": "019eec4b9fa12770127e5bf15895640f93b8c6aaae4fec2dc575a2969f3d6d03", "ref_doc_id": "32a92ec0-51a7-4325-afbf-7964259752a1"}, "f9b94697-bc8e-45da-b9d2-53a784e4c144": {"doc_hash": "6ec43ddae8288f04b9a40bc72526e44c2fefcb43572c855e763bab19f8124704", "ref_doc_id": "f4c367a5-8e03-4981-8d10-e577efa17c6d"}, "3455efc6-2d7c-4c93-a8a4-f0b1bfbc7b90": {"doc_hash": "c0e9e3f4a81c10bdb519ed6ae0e5c0f3193f6b2628bb34aea094d5272343173d", "ref_doc_id": "8f65c141-4a20-4b4d-b945-bfe013e121f2"}, "2276bb05-eed2-490d-beb4-a0d51870171f": {"doc_hash": "188330a13401df975dbb56ebafb76815d0f38f2980dcd67362ae17653a21f63d", "ref_doc_id": "07d95561-d14c-499b-966d-0d03d75e7d29"}, "d15d7fa3-aadc-4c30-ac00-9de947585d0e": {"doc_hash": "54678c6a0452d4ba5a5abd96dc676d71aabb370c1d4cca6e7985f5adc323cada", "ref_doc_id": "85c9ae0e-3931-457f-9c7c-3e9a99677b3f"}, "3720fd6b-6b28-4a36-a1cf-44ab1ecb8181": {"doc_hash": "17c7c013b0ae781776e03cbb9fe73a8f8256b934bf1ce3ab2203a9275a146bd3", "ref_doc_id": "86a20e20-d169-455e-9851-3c0fd1e349f7"}, "0008012f-39e0-42e2-8cad-790093e25627": {"doc_hash": "7b53a0955ba3d9bcbb20df7c4be29e308eeed8f21a6ff3b0af10b0bce03c1c6b", "ref_doc_id": "33edf4a4-5010-4d67-a387-7db9d38877c0"}, "d6d140b3-c392-4c2d-b42e-303a1a2e1dd5": {"doc_hash": "ba1e693f48ec64fde00ed6cd572f99f03b953f7eb5d21bc9a6774d3a71d521c1", "ref_doc_id": "51184805-c391-407c-b8ab-43ef952e090e"}, "e729a7a7-b3f7-4c66-bc90-6679cda7deb7": {"doc_hash": "27f7bb358be12934fad22334cf92ddaca07d62d29c5a9aa67e1086287404795c", "ref_doc_id": "515b3860-179f-4d79-aa5f-c7af37b77a69"}, "90f9a33b-6e32-40c6-ad67-a095f234e930": {"doc_hash": "c7a36a57df728d047f2856697fccf71e3e8729644b54143cc2e4d99a417e72a8", "ref_doc_id": "825bc117-ff0a-42be-9d9f-35c8bbac21ba"}, "b0fbef65-ecf3-4a97-9aac-cea5a5f485a2": {"doc_hash": "ef18a7818be86b878ac229c21b10fabdc49721adaf7e851d50efe3c114c0b885", "ref_doc_id": "07754aab-2daf-46b0-9cfb-75a40022faf2"}, "716ee2d5-bec8-4526-b174-f26e717eae35": {"doc_hash": "caf40511fe1004c63594914143588489cc5930d7f92fd060a2b37924bd3fab75", "ref_doc_id": "480f028e-4b50-4e77-9fab-3ca65be81ffe"}, "b59af04f-a898-4d4c-a853-6f07430c8625": {"doc_hash": "0515d8dfd7115dc97fb8dddf443a2b8e52da66eb32c432aa9195ee069ce843ac", "ref_doc_id": "f986cd49-070b-4d42-ac9b-cd894a9d834e"}, "108eb530-ce90-406e-a77b-b42a08425f15": {"doc_hash": "ffe932de948ff99b8a1b56278876b01cc5518b61b41ff505b44f9f5c64eb3a44", "ref_doc_id": "ddc54b96-3ab6-4f99-8e78-a6437c6d1877"}, "63464ff0-9287-4d99-b86f-1aa7f1731ad2": {"doc_hash": "8e5d4925f88fca8292b4c4a362c694c4f1b6428b77e9d9e26cec0e0b70c5c2f6", "ref_doc_id": "09a23a89-d6e1-4b37-9770-96bbe87560b8"}, "f23c8bb0-7732-42c2-94ce-bec01b30ab41": {"doc_hash": "78ddec992b65ac7c7c7a0bff2a3295e96595193dd03567eeb896973971ba4e40", "ref_doc_id": "bab6e1af-7013-497b-984a-62fbc119b94b"}, "4b33678c-d8c5-4162-ac14-b3ced1d0cce8": {"doc_hash": "f6b77d335f28bd726d861ffffcbd1f72430b40dedaa348c928f332cc169572c9", "ref_doc_id": "fad18478-0f39-4f3c-a26c-6e7417c6bc30"}, "cca9fd02-6789-4746-abab-e1a79d930cc7": {"doc_hash": "b733fe4d929631d1b27e8d50474548d4038ca0247a448f0b6fbb15e1e3cca55e", "ref_doc_id": "bca5d914-8363-4775-aa79-0dbcf482ef98"}, "e64b2b10-79c9-4498-b5fc-b5257c6102ef": {"doc_hash": "7a09afc4b833bce10d503c10d7299fb45d93da2bbe93c8a7f548e21a16f8e95d", "ref_doc_id": "0718ecd1-aaa4-4496-b175-b691c8ec8833"}, "8b179273-dbca-4a7b-bd6f-b91ea559c337": {"doc_hash": "3c6a203f6d3a062b913d6e02073ae7357227732ef568b636aa3e3bccbf46fa84", "ref_doc_id": "0a8126e6-ef15-4069-9014-9377e77bd8db"}, "366c7e0d-b386-459b-8f55-22adb0967d30": {"doc_hash": "263d9a1004b8ce973a20eb0e1f61fbe436c8384e3958682d82efce485e6ee14b", "ref_doc_id": "8e6ff787-6761-4b6a-b47e-a803bb22633f"}, "75c59af7-e82e-437a-9c8a-bc6809ece297": {"doc_hash": "20f64ed18bb1c0035261122f0fdbccb6f7c4a152bbf5343a258b6173926b2e74", "ref_doc_id": "a2fb9a64-965e-44fc-b82c-f8bb58aed32c"}, "c3ebf273-b0c3-4eb0-833f-305089a7abf5": {"doc_hash": "d2a40ebc38d9a74bfbc7929f0e8eac771f00a6b6457a5b469590bbbe67ae3504", "ref_doc_id": "626fd3ce-52cf-46df-bd55-c7979f3387b5"}, "94b717cf-0e7a-4af1-b02e-5d896e9ee8ff": {"doc_hash": "bc55bceffaa3c63f0b2f303b5c6e79b1aa9b8fd7944dfd94d1f4897021d1fbd6", "ref_doc_id": "69c3357b-940f-4cf6-98b1-0ffc12680b76"}, "a321271c-f947-439f-92ee-2f91623939d3": {"doc_hash": "951940de76ac2320ce643916d7ccdb065c477abbf9ce38a74d8accf62ba40b35", "ref_doc_id": "d00cd52c-48dc-458b-9461-63bed191d1e9"}, "a1aafc7c-c342-4a1c-8039-9e471d8caaae": {"doc_hash": "13fc503a06e236b1f0fa379fcd7030c4a86ac2efe22448d1ac15ba7465502790", "ref_doc_id": "fb58b84b-0bc3-47a0-b8be-951afaf2f4d6"}, "bfbf5b89-632f-4a9d-a345-fe1a37b01dbf": {"doc_hash": "03e6a5a6717da947f04a7a8626b663fd1b8da5affcfc6a9af279852ee3c6730d", "ref_doc_id": "f76c1a1d-6034-4baa-9a23-b67b5202f40e"}, "9c434ab9-2e36-49dc-ab3d-ade85752eabe": {"doc_hash": "04706d49995a6698a0e1819357e827538836e8a7b4a6e6a0a06f71ba5563d045", "ref_doc_id": "3efc6a40-a67d-4302-8a96-b5b6fc28415b"}, "4a09fc11-5a5d-45e4-a172-cee625ba4634": {"doc_hash": "232ee8829f655df886573aa1d6816e973d81014ea8cda59631095c7b2afe88cc", "ref_doc_id": "64402d25-895d-45d9-9695-c3c7ae6162fe"}, "d2c45121-255c-4a44-86f2-956425f569a4": {"doc_hash": "4e7d77ae00b4de99828f4949da47fe8a85b5f782c6fcf9e43ef68bb230cdeb9b", "ref_doc_id": "3ce22e43-adb2-43cb-bd8a-67ffc57caefc"}, "cb1f88e3-072f-428a-877e-df0892599412": {"doc_hash": "5094c3f961fcbec53710d42cc6a43f9be084e9eea7159c6aae11d0c914d71b17", "ref_doc_id": "ce3cb6ab-8fbe-4b47-99d2-8c5ba4e19a7d"}, "c458f722-7c61-4af9-b72a-95e11791d4aa": {"doc_hash": "3c6a203f6d3a062b913d6e02073ae7357227732ef568b636aa3e3bccbf46fa84", "ref_doc_id": "5f30f38c-7a63-4baf-89f3-6b75728d8ea4"}, "cededcaa-1d1b-4458-ae93-b826a08204b2": {"doc_hash": "1bab4215b6d08764dce9cf4395c69cb2cee8ce6f2e850744de5c8ed5b28df462", "ref_doc_id": "92e960f6-092d-479b-aa01-55aec4130a70"}, "497c5bb0-0c83-4751-95ab-56103e2df367": {"doc_hash": "effe2b38df31ea8b93f54725e6cd1b7dc766c0bd15e09f95b51c58c41532e030", "ref_doc_id": "a8c94450-1b41-4e27-b5da-497cc15d07fc"}, "0c755704-3f45-4582-8f2d-9b09fd836ae6": {"doc_hash": "caf40511fe1004c63594914143588489cc5930d7f92fd060a2b37924bd3fab75", "ref_doc_id": "f6ae0ff4-9c4f-4870-952a-efb73935703d"}, "76eee6fc-ca4b-4b6b-ae7f-e076b2edc5b6": {"doc_hash": "13fc503a06e236b1f0fa379fcd7030c4a86ac2efe22448d1ac15ba7465502790", "ref_doc_id": "9b6e527d-f83b-4095-848f-44ea0803e244"}, "6bc1f391-39aa-4fc8-b3dc-07271ddec689": {"doc_hash": "03e6a5a6717da947f04a7a8626b663fd1b8da5affcfc6a9af279852ee3c6730d", "ref_doc_id": "575791d3-021b-4569-9de9-d1b0afdcdf0d"}, "367b9265-b730-44a3-9149-8b4661346844": {"doc_hash": "3c6a203f6d3a062b913d6e02073ae7357227732ef568b636aa3e3bccbf46fa84", "ref_doc_id": "af5a7a84-a0ba-4ac0-8ea8-36502e81ccbe"}, "adac1fbd-1731-43ee-81b7-883f8f6d7b16": {"doc_hash": "ef18a7818be86b878ac229c21b10fabdc49721adaf7e851d50efe3c114c0b885", "ref_doc_id": "045b78b1-9c84-4a29-8bf7-64c94e60e9be"}, "7ad3c40f-09b7-4de9-b8e3-90ae703d13e8": {"doc_hash": "446cdf109e29bf2c0c576354c227e33fbf355e2544f3081bc0080a4a32524dae", "ref_doc_id": "3c86e01d-19ee-4dde-bd3d-07fda3d2da7a"}, "93cbeb7b-8704-426a-89b2-c998e3a7632b": {"doc_hash": "e856cd13b9497d768206ef25b48a67dee099f5f85a30cf8bd99cad4e4e7a2c57", "ref_doc_id": "7570211d-85c8-49da-99e1-dc3f037d83f4"}, "82e83df3-1a02-41f0-8348-0f2521b29db2": {"doc_hash": "fa0f9399603098fe6e8559d7fa383c80636357c6b035e6bf242bd60db3c94088", "ref_doc_id": "6bfa7dcd-dc94-4b23-9257-141945c3cb48"}, "d774b46c-11d7-4ecb-850f-8d88a02d8b57": {"doc_hash": "446cdf109e29bf2c0c576354c227e33fbf355e2544f3081bc0080a4a32524dae", "ref_doc_id": "463d7c25-6d92-4c5c-8eee-9cc27fb0bd6e"}, "ce86acb4-4045-4b65-9c14-2d460df29c9e": {"doc_hash": "e856cd13b9497d768206ef25b48a67dee099f5f85a30cf8bd99cad4e4e7a2c57", "ref_doc_id": "a6692b3f-56dd-4ef4-844c-31bac5698b03"}, "0a569a32-4af5-468b-9e3f-8bdc251131e3": {"doc_hash": "fa0f9399603098fe6e8559d7fa383c80636357c6b035e6bf242bd60db3c94088", "ref_doc_id": "5ccfc505-d8c2-43ad-817e-e36d7300b179"}, "079244c3-02cc-46fa-93aa-afbe0af52da7": {"doc_hash": "4555008cbbdd132ceec409ecfe1743e99c9f4e109c5041cac03fceaad032ab57", "ref_doc_id": "9a4862c0-2c36-41df-8ad4-981878441600"}, "a184d45a-d98f-4f7e-9938-9e41199ecaaf": {"doc_hash": "f6c1c7ce5e449dfb2307c80be4fbb3119d76c77359430885b886fafeb82b8d37", "ref_doc_id": "0c072d0a-6a98-4e1a-a7cd-79b9c71589ad"}, "e49072e5-34cd-4298-b0a8-abdf58853728": {"doc_hash": "1e2304cf2d5eb2d02a90eebe87d5dc1b4b7fbe64c3dac8215b4bb88b6306d141", "ref_doc_id": "6fd149d8-f196-4892-abae-fe698f01916a"}, "95ccbbc2-0be8-4b3f-93c1-db7fa562be06": {"doc_hash": "4555008cbbdd132ceec409ecfe1743e99c9f4e109c5041cac03fceaad032ab57", "ref_doc_id": "ed943ff1-0464-4398-bf7a-0d8fbbeca0d3"}, "cb1a559b-f2dd-4eae-8171-484d192a10ba": {"doc_hash": "0fa38f4c33664e68edec1fa049f499e30a6c2d4977ffcd4487a9840cde8f157e", "ref_doc_id": "c2a9410d-1021-4b1d-8e37-76dccb721b03"}, "1d7b12b3-027e-4681-b378-f42125d6e048": {"doc_hash": "a67a4dd5c22d0c94ce22303c56abdca232e215cb04afdbc0a6fb5d732d3728d7", "ref_doc_id": "c7c7a898-be6e-4468-8923-0f77a490f21b"}, "eceb91ce-d5d1-4271-8c60-be68a824cad1": {"doc_hash": "5730581b68813300c56bea04f35d25cbd89f95e9842c1d8d4bafa56f74d2bf90", "ref_doc_id": "e6bdfe42-9113-47df-b54e-67412f7c081b"}, "58732b24-265a-4cdd-91ca-9f56d5b78e9e": {"doc_hash": "3826a13ff3b5b0594b89b17ee2e780ae6e9fd1b82350f74dda4c8626002a75f9", "ref_doc_id": "d7e62501-a8c4-4a6e-a73e-25a3c43e674e"}, "b276f0a5-a5cd-4b54-b22e-ce4bc66ffbd2": {"doc_hash": "96942c5fb45165f7ac206f43574f36ca14617296d7e8e5d70ba9bff3a67405fe", "ref_doc_id": "d7bcf9d5-4a1a-4699-ba6c-bee2cdc9f4f2"}, "a17965d4-a342-4265-976f-b35b406e58f4": {"doc_hash": "c751c6ed4e39363fe4bc23e6f8e498696f7fd2d9a071686a645418ec48f44635", "ref_doc_id": "b6293498-5a80-4cd9-867a-a96a606120c7"}, "ea739c0a-c962-407a-9659-53d0ffb709c5": {"doc_hash": "5d84e33f83ebb1b138cce0062a41e7ff2f52406d98117edd3df46cb288c5c4b4", "ref_doc_id": "86c69809-b181-46bf-97fb-cd56e19ce40a"}, "e36e1915-4716-4ec7-8263-9389511f550b": {"doc_hash": "6b3f4e7747fa5ef09bb5bfd4913082adb71d96926912cba1fa32cf786d01fe89", "ref_doc_id": "ffc793a0-da1d-4e88-a2a1-51691fcf509a"}, "264dc903-d521-4dd9-8ad0-6d7be3478de9": {"doc_hash": "7991fa0045813e171b11d63163eed278d4cfff165d0a7ead008efd7223d11881", "ref_doc_id": "463571c9-bab0-44a7-a4c9-9782851b527a"}, "5eb7149f-7f21-4510-ba90-775b0fa540b6": {"doc_hash": "2b612fca87951d38f6c0040d4c8622ff0558b78ab7b0876b1501a9ec5d027f56", "ref_doc_id": "63660035-afd4-49a0-9037-19a6544bd45e"}, "be6176ac-c745-4347-9617-1cbf126a057b": {"doc_hash": "d47a29dec6b5ab3470f993d5e9aefd9fb66050805667443336c9f3a8929aa971", "ref_doc_id": "0a8d410b-a401-4b20-9834-167ece82cebc"}, "b9173d09-2e52-40e5-91db-5373d7282fa7": {"doc_hash": "5f15d8188f87ef89b30aa8a3f599010f717d2cd775cee18c9f8bfd0b75f0beae", "ref_doc_id": "4afe26dd-d1bc-4481-9832-6cc606f78391"}, "e9a12905-d0e8-4eff-8dec-f59247d836ff": {"doc_hash": "caf40511fe1004c63594914143588489cc5930d7f92fd060a2b37924bd3fab75", "ref_doc_id": "80fca3a0-4dfa-411f-bbb6-cd2f625818fb"}, "b349cd00-567e-458b-9647-49be010a141f": {"doc_hash": "661244b0b2676ea051b9ff7edc47b6d82eb4f3a6b388f4b7f246d1334965087e", "ref_doc_id": "a0272232-94c8-4747-a942-8e0ee6b62ccc"}, "ef573871-63fb-403a-b264-c3945ce09bc6": {"doc_hash": "72c8c886a622c2bdfaf583d5e64a6a9f7828d403c2436aa4c38a0c6f58574a96", "ref_doc_id": "aed126ba-a4fa-4b2c-b857-3ceed2e5e5ec"}, "4671e372-227e-479d-8cde-8b57125af1d1": {"doc_hash": "403dff934e7fc99c7b579a39627827a1d1f7d1ccc56fe78edb757ba3b864df97", "ref_doc_id": "c38c3e6f-110e-41f5-98df-fdf5a2d1eac5"}, "4363af07-5f74-4fd3-9a26-570ec037f2ee": {"doc_hash": "b76a587804c15fad482728ea5c0591098c01e0ffa23633895e81bf35d9a71a57", "ref_doc_id": "92371eb7-be2c-4107-b52d-c3f5a2366918"}, "5e180497-af30-4447-931d-becd277c1a3a": {"doc_hash": "5d11a2bf298ccb03fbbc3eae40042bb349d2707d4503c7e37914d58d308c3c14", "ref_doc_id": "f18e879a-48ae-44ce-a2af-543a3b26af23"}, "d84495bd-3662-4e8b-a1ce-8b29093c0d8f": {"doc_hash": "7746769ef3b068fca1d265c3de7acea4e4c00c0b349b574799cb67e92239b7cc", "ref_doc_id": "46bf9d8e-8bb7-46de-bafb-d855f44a4096"}, "dd372a99-ae25-4c7c-913b-646eefe2b45a": {"doc_hash": "aa0c74684b7b1f3f65bc2c87c0058e300d7df1e3eaad9e17532db6938841de6a", "ref_doc_id": "e4e387fe-96f4-49ce-9a6e-9f9e5fc4e0e1"}, "a70266cd-acd6-429f-a95a-b77e844728e6": {"doc_hash": "5760669264a2c603ae2f8ba5ee015603fdea155d94ce061c9454500b19c5545f", "ref_doc_id": "c3239938-f567-4119-8c83-bd0950043528"}, "3f40c087-0f2c-4052-b5ed-df4ee4f04dda": {"doc_hash": "5ee0f3eab27b994229bc145ef5dccd23a60cd02ee5941048f6651483ac210129", "ref_doc_id": "d199bceb-69c6-40f1-8c0c-f38cedd54f65"}}, "docstore/data": {"1f8a1b4a-bb8e-4a09-a7d6-c24fb34821e1": {"__data__": {"id_": "1f8a1b4a-bb8e-4a09-a7d6-c24fb34821e1", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "379a7942-d426-4d60-a7cd-d4ce1dafcd41", "node_type": "4", "metadata": {}, "hash": "6985aae14069a604a8a243f9652a7fb4624ecdfb29111544e27b070415d22dcd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "INTERACTS WITH (S)-nicotine (ortholog); DDT (ortholog); formaldehyde (ortholog)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 79, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "566ff003-e9c6-421e-ab87-7b01605105d7": {"__data__": {"id_": "566ff003-e9c6-421e-ab87-7b01605105d7", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b459346f-b701-49a9-ba4c-becbd4f6eef8", "node_type": "4", "metadata": {}, "hash": "ef4d61a32bc24dbdfd6f2a8b13c5a1901aaaf84f16153da370be10a870b3bf84", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "ENCODES a protein that exhibits nucleotide phosphatase activity, acting on free nucleotides (ortholog); phosphatase activity (ortholog); polynucleotide 5'-phosphatase activity (ortholog); INVOLVED IN polynucleotide 5' dephosphorylation (ortholog); protein dephosphorylation (ortholog); RNA metabolic process (ortholog); FOUND IN fibrillar center (ortholog); intercellular bridge (ortholog); nuclear speck (ortholog); INTERACTS WITH (S)-nicotine; 2,3,7,8-tetrachlorodibenzodioxine; 4,4'-diaminodiphenylmethane", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 508, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7d3e29da-89a0-4112-84a9-6c2ed1139717": {"__data__": {"id_": "7d3e29da-89a0-4112-84a9-6c2ed1139717", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2b70ecd1-b2bd-4753-b17c-f1426aca769d", "node_type": "4", "metadata": {}, "hash": "07eeebd80ac7237292031e2bbf9bb211491f5c2ae38c08ee993f5ebc33856421", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Exhibits miRNA binding activity. Involved in production of miRNAs involved in gene silencing by miRNA. Predicted to localize to the nucleus. ENCODES a protein that exhibits miRNA binding; INVOLVED IN posttranscriptional regulation of gene expression; production of miRNAs involved in gene silencing by miRNA; ASSOCIATED WITH schizophrenia; FOUND IN nucleus (inferred); INTERACTS WITH (S)-nicotine; aflatoxin B1; benzo[a]pyrene diol epoxide I", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 441, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4a3ad329-9f70-4f8a-83cf-befe036a4a46": {"__data__": {"id_": "4a3ad329-9f70-4f8a-83cf-befe036a4a46", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a189ad72-2a7e-43a4-9ab0-2310630984ab", "node_type": "4", "metadata": {}, "hash": "a0630ae607f91f75360b70543422a289cd1818c014877e528f5dba6d11afb3db", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "ENCODES a protein that exhibits miRNA binding; INVOLVED IN posttranscriptional regulation of gene expression; production of miRNAs involved in gene silencing by miRNA; ASSOCIATED WITH schizophrenia; FOUND IN nucleus (inferred); INTERACTS WITH (S)-nicotine; aflatoxin B1; benzo[a]pyrene diol epoxide I", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 300, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5b962085-5130-4e8d-a4b0-140ed4db2936": {"__data__": {"id_": "5b962085-5130-4e8d-a4b0-140ed4db2936", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8a1c836b-d65d-440a-8f99-22f1348c46b8", "node_type": "4", "metadata": {}, "hash": "4de6a61d3906cb23d20db5ea8091cd9e2e39bd97754d9d497309086120dab8a5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Background\\nExposure to second hand smoke (SHS) is one of the major causes of premature death and disease among children. While socioeconomic inequalities exist for adult smoking, such evidence is limited for SHS exposure in children. Thus, this study examined changes over time in socioeconomic inequalities in infants\u2019 SHS exposure in Japan.\\nMethods\\nThis is a repeated cross-sectional study of 41,833 infants born in 2001 and 32,120 infants born in 2010 in Japan from nationally representative surveys using questionnaires. The prevalence of infants\u2019 SHS exposure was determined and related to household income and parental education level. The magnitudes of income and educational inequalities in infants\u2019 SHS exposure were estimated in 2001 and 2010 using both absolute and relative inequality indices.\\nResults\\nThe prevalence of SHS exposure in infants declined from 2001 to 2010. The relative index of inequality increased from 0.85 (95% confidence interval [CI], 0.80 to 0.89) to 1.47 (95% CI, 1.37 to 1.56)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1017, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ad6d9332-1f2f-44fd-8d75-ac976234fb18": {"__data__": {"id_": "ad6d9332-1f2f-44fd-8d75-ac976234fb18", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "52b88f37-a79a-4ab6-84ba-e169a631b807", "node_type": "4", "metadata": {}, "hash": "2d67d85ddbbeff88f3c7c5a892d21eaed5e3ad3a36b7dc171d6586b128435d70", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "based on income and from 1.22 (95% CI, 1.17 to 1.26) to 2.09 (95% CI, 2.00 to 2.17) based on education. In contrast, the slope index of inequality decreased from 30.9 (95% CI, 29.3 to 32.6) to 20.1 (95% CI, 18.7 to 21.5) based on income and from 44.6 (95% CI, 43.1 to 46.2) to 28.7 (95% CI, 27.3 to 30.0) based on education. Having only a father who smoked indoors was a major contributor to absolute income inequality in infants\u2019 SHS exposure in 2010, which increased in importance from 45.1% in 2001 to 67.0% in 2010.\\nConclusions\\nThe socioeconomic inequalities in infants\u2019 second hand smoke exposure increased in relative terms but decreased in absolute terms from 2001 to 2010. Further efforts are needed to encourage parents to quit smoking and protect infants from second hand smoke exposure, especially in low socioeconomic households that include non-smoking mothers.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 876, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9c122296-d245-4c54-a42b-82163b1b8b93": {"__data__": {"id_": "9c122296-d245-4c54-a42b-82163b1b8b93", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1e0ce963-25d3-4f79-8244-c2d6ac4b0195", "node_type": "4", "metadata": {}, "hash": "d20b8486923297ba699e36c282d4d9a0822fb21f162c41ec47d27f349596716b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "ASSOCIATED WITH hereditary spastic paraplegia 4 (ortholog); FOUND IN endoplasmic reticulum (ortholog); Golgi apparatus (ortholog); intracellular membrane-bounded organelle (ortholog); INTERACTS WITH (S)-nicotine; 2,3',4,4',5-Pentachlorobiphenyl; 2,3,7,8-tetrachlorodibenzodioxine", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 279, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9935b7e9-6b2a-4f59-b82f-6aab5d775c93": {"__data__": {"id_": "9935b7e9-6b2a-4f59-b82f-6aab5d775c93", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "eb101c39-4be2-463b-bc2c-43fddb5d4189", "node_type": "4", "metadata": {}, "hash": "a3de013655e8b8d353ff2d103229bf417198ae0efdb8b5fdb59743205cbc60fe", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"FOUND IN cytosol (ortholog); INTERACTS WITH bisphenol A; vinclozolin; (S)-nicotine (ortholog)\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 97, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d0da3769-8197-454d-b6a3-1603946c9630": {"__data__": {"id_": "d0da3769-8197-454d-b6a3-1603946c9630", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f7b640a4-06ea-4603-a995-3e1d426bdb29", "node_type": "4", "metadata": {}, "hash": "62b4cb49c8d163c652c70e93d3798a754ef64c6c53aeafedcd0b73a459daeec0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ENCODES a protein that exhibits RNA binding (inferred); FOUND IN cytosol (ortholog); INTERACTS WITH (S)-nicotine; aflatoxin B1; ethanol\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 139, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2db3b3fa-1725-46e9-9363-ff0184a237f9": {"__data__": {"id_": "2db3b3fa-1725-46e9-9363-ff0184a237f9", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "525d253d-709c-4846-85ed-050168e9b353", "node_type": "4", "metadata": {}, "hash": "7d30d8af654cd292a28d587b0a881163dc122757507a7c6adf2b1f3dd52ed422", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"A series of phenanthroquinolizidine alkaloids 1\u201324 were prepared and first evaluated for their antiviral activity against tobacco mosaic virus (TMV). The bioassay results showed that most of these compounds exhibited good to excellent in vivo anti-TMV activity, of which compounds 1, 2, 15 and 16 displayed significantly higher activity than (R)-antofine and commercial Ningnanmycin at the same test condition. The substituents on the phenanthrene moiety play an important role for maintaining high in vivo antiviral activity. The introduction of 6-hydroxyl, which is proposed to interact with TMV RNA, did increased anti-TMV activity. The 14aR-configuration was confirmed to be the preferred antiviral configuration for phenanthroquinolizidine alkaloids. Introduction of hydroxy group at 15-position of phenanthroquinolizidine alkaloids increased activity for S-configuration but decreased activity for R-configuration. Present study provides fundamental support for development and optimization of phenanthroquinolizidine alkaloids as potential inhibitors of plant virus.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1077, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "58479ebc-7ccc-4212-a2b7-4e3dc92639e8": {"__data__": {"id_": "58479ebc-7ccc-4212-a2b7-4e3dc92639e8", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b88ac031-8b9a-40ee-8b4f-d46457879876", "node_type": "4", "metadata": {}, "hash": "f746e9b9a3cf5c29ae4ed7d135028b6fb7bd9d0286eca83cbebd3c804b4982f5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ENCODES a protein that exhibits mRNA binding (ortholog); INVOLVED IN positive regulation of RNA splicing (ortholog); ASSOCIATED WITH abnormal memory T cell morphology; abnormal memory T cell physiology; abnormal T cell differentiation; ASSOCIATED WITH RASopathies (ortholog); INTERACTS WITH (S)-nicotine; 1-chloro-2,4-dinitrobenzene; 17alpha-ethynylestradiol\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 362, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ff389915-24b9-4cc0-b702-9350b6bb9a79": {"__data__": {"id_": "ff389915-24b9-4cc0-b702-9350b6bb9a79", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cc6a8cb5-a714-4c19-854d-448b4e7facc1", "node_type": "4", "metadata": {}, "hash": "c3eb931dc9826e01e04cd32806719c8d47a61e71ddc0a3396830c4011cdae0e0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Exhibits RNA binding activity. Predicted to be involved in mRNA splicing, via spliceosome. Localizes to the nucleoplasm. ENCODES a protein that exhibits RNA binding (inferred); INVOLVED IN mRNA splicing, via spliceosome (inferred); RNA processing (inferred); PARTICIPATES IN spliceosome pathway; ASSOCIATED WITH Experimental Liver Cirrhosis; FOUND IN nucleoplasm; nucleus; INTERACTS WITH (-)-demecolcine; (S)-nicotine; 2,3,7,8-tetrachlorodibenzodioxine\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 456, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5149fba1-44cb-462e-bca7-d2d8d7c480e5": {"__data__": {"id_": "5149fba1-44cb-462e-bca7-d2d8d7c480e5", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f78d6af1-a210-4614-8709-dadee648219e", "node_type": "4", "metadata": {}, "hash": "b8792b0ff66894a43af49d8ecb1ba9b0359c1efa2955ce629c6126908efabf2b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ENCODES a protein that exhibits RNA binding (inferred); INVOLVED IN mRNA splicing, via spliceosome (inferred); RNA processing (inferred); PARTICIPATES IN spliceosome pathway; ASSOCIATED WITH Experimental Liver Cirrhosis; FOUND IN nucleoplasm; nucleus; INTERACTS WITH (-)-demecolcine; (S)-nicotine; 2,3,7,8-tetrachlorodibenzodioxine\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 335, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d18b1e00-33ad-4c77-bd3e-9f68b5e8e5a8": {"__data__": {"id_": "d18b1e00-33ad-4c77-bd3e-9f68b5e8e5a8", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "68f5f365-9515-440f-99d0-d0a7d7f744f4", "node_type": "4", "metadata": {}, "hash": "6ff8a77f1dc42daf88d71f361f05dac644a3caa1bfb328036db2e76a8bc3e486", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"To understand whether any human-specific new genes may be associated with human brain functions, we computationally screened the genetic vulnerable factors identified through Genome-Wide Association Studies and linkage analyses of nicotine addiction and found one human-specific de novo protein-coding gene, FLJ33706 (alternative gene symbol C20orf203). Cross-species analysis revealed interesting evolutionary paths of how this gene had originated from noncoding DNA sequences: insertion of repeat elements especially Alu contributed to the formation of the first coding exon and six standard splice junctions on the branch leading to humans and chimpanzees, and two subsequent substitutions in the human lineage escaped two stop codons and created an open reading frame of 194 amino acids. We experimentally verified FLJ33706's mRNA and protein expression in the brain. Real-Time PCR in multiple tissues demonstrated that FLJ33706 was most abundantly expressed in brain. Human polymorphism data suggested that FLJ33706 encodes a protein under purifying selection. A specifically", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1082, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a5059593-19bf-440d-bc3e-c4302034d845": {"__data__": {"id_": "a5059593-19bf-440d-bc3e-c4302034d845", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "75f276b1-dc73-448d-b3df-f2949ebae042", "node_type": "4", "metadata": {}, "hash": "eee08280146e410a372bdbb5701db8087bd9481f93d699f4066a22a0ea44bc7e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "designed antibody detected its protein expression across human cortex, cerebellum and midbrain. Immunohistochemistry study in normal human brain cortex revealed the localization of FLJ33706 protein in neurons. Elevated expressions of FLJ33706 were detected in Alzheimer's brain samples, suggesting the role of this novel gene in human-specific pathogenesis of Alzheimer's disease. FLJ33706 provided the strongest evidence so far that human-specific de novo genes can have protein-coding potential and differential protein expression, and be involved in human brain functions.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 577, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e4b2144b-4676-477c-9fcf-3f16ca35a752": {"__data__": {"id_": "e4b2144b-4676-477c-9fcf-3f16ca35a752", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9ebcde90-cd9f-4577-b66e-0492708e0483", "node_type": "4", "metadata": {}, "hash": "9333fa05f8168ba21743c164403efe6424d0c1f1bd5555dbe8f1205ff3ddc0b5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"The Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) is a resource developed to facilitate research on genetic and environmental factors on common diseases and healthy aging. The RPGEH resource links biospecimens, health surveys, and comprehensive electronic medical records on broadly consented adult members of Kaiser Permanente Medical Care Plan, Northern California Region (KPNC). KPNC is an integrated health care delivery system with a membership of approximately 3.3 million people in northern California. The membership of KPNC is representative of the general population in the 14 county area in which facilities are located, although extremes of income are underrepresented. At the end of 2013, the RPGEH resource included: (1) demographic and behavioral surveys from over 430,000 participants; (2) biospecimens (DNA, serum, plasma, and/or saliva) from over 204,000 participants, including over 13,000 pregnant women; (3) genome-wide genotype data (70 billion SNP genotypes) on over 100,000 participants, including the Genetic", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1066, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a20600b6-e2cf-4dcc-94b1-41b1f8d0a1ae": {"__data__": {"id_": "a20600b6-e2cf-4dcc-94b1-41b1f8d0a1ae", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "10c759b9-62c2-403f-b566-b50f9b521dd0", "node_type": "4", "metadata": {}, "hash": "2af7a040187105b9c4f8b0f9454fe7a021f84da3a66a614999a56020a7f1c789", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Epidemiology Research on Adult Health and Aging (GERA) cohort; and (4) the longitudinal electronic medical records of the participants. The RPGEH was developed beginning in 2005 at the Division of Research of Kaiser Permanente Northern California by Catherine Schaefer (Director), Neil Risch (Co-Director), Lisa Croen, Eric Jorgenson, Lawrence Kushi, Charles Quesenberry, Sarah Rowell, Carol Somkin, Stephen Van den Eeden, Larry Walter, and Rachel Whitmer. Funding of the RPGEH was provided to C. Schaefer (PI) and N. Risch (co-PI) by the Wayne and Gladys Valley Foundation, The Ellison Medical Foundation, the Robert Wood Johnson Foundation, Kaiser Permanente Northern California, and the Kaiser Permanente National and Regional Community Benefit Programs. The GERA cohort was funded by a grant from NIH to RPGEH and UCSF (RC2 AG036607; C. Schaefer and N. Risch, PIs). At the time of the award of the RC2 project in late 2009, the RPGEH had established a cohort of", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 965, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fff52cff-78ea-4507-b56e-49e61f916d47": {"__data__": {"id_": "fff52cff-78ea-4507-b56e-49e61f916d47", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1b520a3e-d95e-473e-bd63-7e54520282b1", "node_type": "4", "metadata": {}, "hash": "00b225c46425f1a4be98bd02ad3f261ff63a1c6461b495f0012c9ba891cbe7a1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "about 140,000 individuals who had answered a detailed survey, provided saliva samples for extraction of DNA, and given broad consent for the use of their data in studies of health and disease. Survey and Cohort Recruitment. Initially, the RPGEH developed electronic disease registries to enable identification of phenotypes, using algorithms applied to EMR data. In 2007, the RPGEH mailed a four page survey to 1.9 million adult (\u2265 18 years old) members of KPNC who had been members for two years or more, to obtain data on demographic and behavioral factors complementary to the clinical data in the EMR. The survey materials included a cover letter introducing the RPGEH, a two page list of Frequently Asked Questions, and the survey, which included questions on demographic factors such as education, race-ethnicity, income and marital status, dietary factors, physical activity, smoking, and alcohol consumption, as well as reproductive history and reproductive health.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 973, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "38d5ffb7-2cb5-4f2d-a464-a530361e5bbb": {"__data__": {"id_": "38d5ffb7-2cb5-4f2d-a464-a530361e5bbb", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c2bb20df-19eb-479c-8207-5232fd6face1", "node_type": "4", "metadata": {}, "hash": "4c8057c395f1a6b506287e882db6c08736800d301a8f6a04d8136869761f65bc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Members whose electronic medical records indicated a preference for written communications in Chinese or Spanish received survey materials both in English and a Chinese or Spanish translation. Approximately 400,000 completed surveys were returned. Saliva Sample Collection. Beginning in July 2008, respondents to the survey were asked to sign and return a consent form and authorization for use and disclosure of protected health information. The consent form authorized broad use of biospecimens, survey data, and data from participants' electronic health records for use in studies of genetic and environmental influences on health and disease. Respondents who returned completed consent forms were mailed (Oragene) saliva collection kits; more than 132,000 saliva samples were collected in two years. Completed saliva kits were scanned and archived in a temporary biorepository at the KPNC Division of Research. In late 2009, the RPGEH began collection of saliva samples from the California Men's Health Study (CMHS), a", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1022, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8c25c87c-a435-4f15-873e-4d44247c4968": {"__data__": {"id_": "8c25c87c-a435-4f15-873e-4d44247c4968", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ee375edc-6a5b-44ba-9063-9fadb3fb3854", "node_type": "4", "metadata": {}, "hash": "b46651a8fea1f75ed6b59a7fcf9f6eecc27a5ec07b76559a0f4f4cb7c2df85ff", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "cohort that had been previously assembled in 2002-2003 and had been excluded from the RPGEH survey mailing with the intent of later adding CMHS participants to the assembled RPGEH cohort. The CMHS was developed to facilitate research on prostate cancer and other conditions in older men; the study protocol is described in Enger, et al., 2006. It enrolled and surveyed more than 40,000 men in KPNC, ages 45-69 years, who were members of KPNC during 2002-2003. CMHS men completed two mailed surveys with demographic and behavioral data similar to that of the RPGEH. The data on analogous variables were reconciled and integrated with the data derived from the RPGEH cohort for use in the RPGEH resource. By 2011, RPGEH collected approximately 15,400 saliva samples from men participating in the CMHS. RPGEH Access and Collaborations Website and Procedures. The RPGEH maintains a web portal for inquiries and applications for collaboration and", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 941, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2d43d55d-ca09-41fc-bb78-8f71dd775f55": {"__data__": {"id_": "2d43d55d-ca09-41fc-bb78-8f71dd775f55", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "32a92ec0-51a7-4325-afbf-7964259752a1", "node_type": "4", "metadata": {}, "hash": "d6d77508e30620273f43ec5e20a9d5fc8b599eef213ac49301dd14f48a8ad66d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "access to data. The url is: https://rpgehportal.kaiser.org/. RPGEH has an application process and an Access Review Committee that reviews applications for collaboration and use. For more information, please contact RPGEH through the website.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 243, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f9b94697-bc8e-45da-b9d2-53a784e4c144": {"__data__": {"id_": "f9b94697-bc8e-45da-b9d2-53a784e4c144", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f4c367a5-8e03-4981-8d10-e577efa17c6d", "node_type": "4", "metadata": {}, "hash": "1d5580db516fb6c656495e2db5c715dd260bb80514d39412107d3141874c71e1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Objectives\\nTo investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event.\\nMethods\\nWe analyzed 211 CIS patients (age: 28.9\u00b17.8 years) enrolled in the SET study, a multi-center study of high-risk CIS patients. Pre-treatment samples were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) early nuclear antigen-1 (EBNA-1), viral capsid antigen (VCA), early antigen-diffuse (EA-D), 25 hydroxy-vitamin D3 and cotinine levels and HLA DRB1*1501 status. The inclusion criteria required evaluation within 4 months of the initial demyelinating event, 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. All patients were treated with interferon-beta. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months.\\nResults\\nThe time to first relapse decreased and the number of relapses increased with anti-CMV IgG positivity. Smoking was associated with", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1086, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3455efc6-2d7c-4c93-a8a4-f0b1bfbc7b90": {"__data__": {"id_": "3455efc6-2d7c-4c93-a8a4-f0b1bfbc7b90", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8f65c141-4a20-4b4d-b945-bfe013e121f2", "node_type": "4", "metadata": {}, "hash": "24c8544948a08e243a50d34bdbe78cf5ff272d2dc35d9b13a70a8be8517b95dc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "increased number and volume of contrast-enhancing lesions (CEL) during the 2-year period. The cumulative number of CEL and T2 lesions during the 2-year period was greater for individuals in the highest quartile of anti-EBV VCA IgG antibodies. The percent loss of brain volume was increased for those in the highest quartile of with anti-EBV VCA IgG antibodies.\\nConclusions\\nRelapses in CIS patients were associated with CMV positivity whereas anti-EBV VCA positivity was associated with progression on MRI measures, including accumulation of CEL and T2 lesions and development of brain atrophy.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 597, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2276bb05-eed2-490d-beb4-a0d51870171f": {"__data__": {"id_": "2276bb05-eed2-490d-beb4-a0d51870171f", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "07d95561-d14c-499b-966d-0d03d75e7d29", "node_type": "4", "metadata": {}, "hash": "ad0854c0b8a2b51083fb8c999ec6d02e462d5d64650bfcf7cb4221b0ba52eb8c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"INTERACTS WITH (S)-nicotine (ortholog); DDT (ortholog); formaldehyde (ortholog)\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 83, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d15d7fa3-aadc-4c30-ac00-9de947585d0e": {"__data__": {"id_": "d15d7fa3-aadc-4c30-ac00-9de947585d0e", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "85c9ae0e-3931-457f-9c7c-3e9a99677b3f", "node_type": "4", "metadata": {}, "hash": "e887813869b56404031b68653bf55382c57a06bd4a91c8c05f72df8477305e45", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Exhibits calcium channel regulator activity. Involved in regulation of calcium ion transmembrane transport via high voltage-gated calcium channel. Localizes to the L-type voltage-gated calcium channel complex. Human ortholog(s) of this gene implicated in malignant hyperthermia. Orthologous to human CACNG1 (calcium voltage-gated channel auxiliary subunit gamma 1). Exhibits calcium channel regulator activity. Involved in regulation of calcium ion transmembrane transport via high voltage-gated calcium channel. Localizes to the L-type voltage-gated calcium channel complex. Human ortholog(s) of this gene implicated in malignant hyperthermia. Orthologous to human CACNG1 (calcium voltage-gated channel auxiliary subunit gamma 1); PARTICIPATES IN arrhythmogenic right ventricular cardiomyopathy pathway; dilated cardiomyopathy pathway; hypertrophic cardiomyopathy pathway; INTERACTS WITH (S)-nicotine; acetamiprid; ammonium chloride.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 938, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3720fd6b-6b28-4a36-a1cf-44ab1ecb8181": {"__data__": {"id_": "3720fd6b-6b28-4a36-a1cf-44ab1ecb8181", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "86a20e20-d169-455e-9851-3c0fd1e349f7", "node_type": "4", "metadata": {}, "hash": "2b5fe89437f69a6d5a80b8deb8789731350beb5ba72485d258342672761e1893", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Rationale\\nEmphysema and osteoporosis are epidemiologically associated diseases of cigarette smokers. The causal mechanism(s) linking these illnesses is unknown. We hypothesized autoimmune responses may be involved in both disorders.\\nObjectives\\nTo discover an antigen-specific autoimmune response associated with both emphysema and osteoporosis among smokers.\\nMethods\\nReplicate nonbiased discovery assays indicated that autoimmunity to glucose regulated protein 78 (GRP78), an endoplasmic reticulum chaperone and cell surface signaling receptor, is present in many smokers. Subject assessments included spirometry, chest CT scans, dual x-ray absorptiometry, and immunoblots for anti-GRP78 IgG. Anti-GRP78 autoantibodies were isolated from patient plasma by affinity chromatography, leukocyte functions assessed by flow cytometry, and soluble metabolites and mediators measured by immunoassays.\\nMeasurements and Main Results\\nCirculating anti-GRP78 IgG autoantibodies were detected in plasma specimens from 86 (32%) of the 265 smoking subjects. Anti-GRP78 autoantibodies were singularly prevalent among subjects with radiographic emphysema (OR 3.1, 95%CI 1.7\u20135.7, p = 0.003). Anti-GRP78 autoantibodies were also associated with osteoporosis (OR", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1250, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0008012f-39e0-42e2-8cad-790093e25627": {"__data__": {"id_": "0008012f-39e0-42e2-8cad-790093e25627", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "33edf4a4-5010-4d67-a387-7db9d38877c0", "node_type": "4", "metadata": {}, "hash": "697e19aeea1239df4ebc0f0ca8d53d4d1b36598022d7f825e4a9c6c293fa0b5c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "4.7, 95%CI 1.7\u201313.3, p = 0.002), and increased circulating bone metabolites (p = 0.006). Among emphysematous subjects, GRP78 protein was an autoantigen of CD4 T-cells, stimulating lymphocyte proliferation (p = 0.0002) and IFN-gamma production (p = 0.03). Patient-derived anti-GRP78 autoantibodies had avidities for osteoclasts and macrophages, and increased macrophage NFkB phosphorylation (p = 0.005) and productions of IL-8, CCL-2, and MMP9 (p = 0.005, 0.007, 0.03, respectively).\\nConclusions\\nHumoral and cellular GRP78 autoimmune responses in smokers have numerous biologically-relevant pro-inflammatory and other deleterious actions, and are associated with emphysema and osteoporosis. These findings may have relevance for the pathogenesis of smoking-associated diseases, and development of biomarker immunoassays and/or novel treatments for these disorders.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 867, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d6d140b3-c392-4c2d-b42e-303a1a2e1dd5": {"__data__": {"id_": "d6d140b3-c392-4c2d-b42e-303a1a2e1dd5", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "51184805-c391-407c-b8ab-43ef952e090e", "node_type": "4", "metadata": {}, "hash": "a8bb2f4d7d024dce9d7bda12b67c025afd9b63e77882a7c22a0dba19aa70ef56", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Plant innate immunity relies on the recognition of pathogen effector molecules by nucleotide-binding-leucine-rich repeat (NB-LRR) immune receptor families. Previously we have shown the N immune receptor, a member of TIR-NB-LRR family, indirectly recognizes the 50-kDa helicase (p50) domain of Tobacco mosaic virus (TMV) through its TIR domain. We have identified an N receptor-interacting protein, NRIP1, that directly interacts with both N's TIR domain and p50. NRIP1 is a functional rhodanese sulfurtransferase and is required for N to provide complete resistance to TMV. Interestingly, NRIP1 that normally localizes to the chloroplasts is recruited to the cytoplasm and nucleus by the p50 effector. As a consequence, NRIP1 interacts with N only in the presence of the p50 effector. Our findings show that a chloroplastic protein is intimately involved in pathogen recognition. We propose that N's activation requires a pre-recognition complex containing the p50 effector and NRIP1.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 988, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e729a7a7-b3f7-4c66-bc90-6679cda7deb7": {"__data__": {"id_": "e729a7a7-b3f7-4c66-bc90-6679cda7deb7", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "515b3860-179f-4d79-aa5f-c7af37b77a69", "node_type": "4", "metadata": {}, "hash": "0eec18d411a4b675038b6978e0c8b2652e35d4c1243ae681eea427b75a267b45", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Predicted to have angiotensin type I receptor activity. Involved in several processes, including cellular response to hormone stimulus; positive regulation of branching involved in ureteric bud morphogenesis; and response to estrogen. Predicted to localize to the plasma membrane. Biomarker of hypertension and renovascular hypertension. Human ortholog(s) of this gene implicated in several diseases, including Alzheimer's disease; artery disease (multiple); cerebrovascular disease (multiple); chronic kidney disease; and sarcoidosis. Orthologous to human AGTR1 (angiotensin II receptor type 1). Predicted to have angiotensin type I receptor activity. Involved in several processes, including cellular response to hormone stimulus; positive regulation of branching involved in ureteric bud morphogenesis; and response to estrogen. Predicted to localize to the plasma membrane. Biomarker of hypertension and renovascular hypertension. Human ortholog(s) of this gene implicated in several diseases, including Alzheimer's disease; artery disease (multiple); cerebrovascular disease (multiple); chronic kidney disease; and sarcoidosis. Orthologous to human AGTR1 (angiotensin II receptor", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1186, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "90f9a33b-6e32-40c6-ad67-a095f234e930": {"__data__": {"id_": "90f9a33b-6e32-40c6-ad67-a095f234e930", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "825bc117-ff0a-42be-9d9f-35c8bbac21ba", "node_type": "4", "metadata": {}, "hash": "37f8ee968585b3669444303e746a502f82aff6d0958148cf6dff8fda0c69ac00", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "type 1); PARTICIPATES IN angiotensin III signaling pathway via AT1 receptor; angiotensin II signaling pathway; angiotensin II signaling pathway via AT1 receptor; INTERACTS WITH (S)-nicotine; 2,3,7,8-tetrachlorodibenzodioxine; 6-propyl-2-thiouracil.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 250, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b0fbef65-ecf3-4a97-9aac-cea5a5f485a2": {"__data__": {"id_": "b0fbef65-ecf3-4a97-9aac-cea5a5f485a2", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "07754aab-2daf-46b0-9cfb-75a40022faf2", "node_type": "4", "metadata": {}, "hash": "38d8c3e53b1fd2b82290f7de62bf44159e3bbeebf5f587f29ec7c77db552ae05", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ASSOCIATED WITH arteriosclerosis (ortholog); Chemical and Drug Induced Liver Injury (ortholog); Parkinson's disease (ortholog); INTERACTS WITH (S)-nicotine; 1-chloro-2,4-dinitrobenzene; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 234, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "716ee2d5-bec8-4526-b174-f26e717eae35": {"__data__": {"id_": "716ee2d5-bec8-4526-b174-f26e717eae35", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "480f028e-4b50-4e77-9fab-3ca65be81ffe", "node_type": "4", "metadata": {}, "hash": "d9e5304c87e2faf71ed14f849c6f743bc6a893bf9c9bc4222085fd3a24fc2267", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ASSOCIATED WITH Cerebral Visual Impairment and Intellectual Disability (ortholog); INTERACTS WITH (S)-nicotine (ortholog); 2,3,7,8-tetrachlorodibenzodioxine (ortholog); 4,4'-diaminodiphenylmethane (ortholog)\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 211, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b59af04f-a898-4d4c-a853-6f07430c8625": {"__data__": {"id_": "b59af04f-a898-4d4c-a853-6f07430c8625", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f986cd49-070b-4d42-ac9b-cd894a9d834e", "node_type": "4", "metadata": {}, "hash": "7b9ec45056603b95ee493183159d1255302a0fe690e71a00e69434f754e6a2a9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Exhibits miRNA binding activity. Involved in production of miRNAs involved in gene silencing by miRNA. Predicted to localize to the nucleus. ENCODES a protein that exhibits miRNA binding; INVOLVED IN posttranscriptional regulation of gene expression; production of miRNAs involved in gene silencing by miRNA; ASSOCIATED WITH schizophrenia; FOUND IN nucleus (inferred); INTERACTS WITH (S)-nicotine; aflatoxin B1; benzo[a]pyrene diol epoxide I\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 445, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "108eb530-ce90-406e-a77b-b42a08425f15": {"__data__": {"id_": "108eb530-ce90-406e-a77b-b42a08425f15", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ddc54b96-3ab6-4f99-8e78-a6437c6d1877", "node_type": "4", "metadata": {}, "hash": "8f6ca984ad937f6864101cfa9ebc65c2b9bd7c42385fc55f0c742a7f21e9f2db", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ENCODES a protein that exhibits miRNA binding; INVOLVED IN posttranscriptional regulation of gene expression; production of miRNAs involved in gene silencing by miRNA; ASSOCIATED WITH schizophrenia; FOUND IN nucleus (inferred); INTERACTS WITH (S)-nicotine; aflatoxin B1; benzo[a]pyrene diol epoxide I\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 304, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "63464ff0-9287-4d99-b86f-1aa7f1731ad2": {"__data__": {"id_": "63464ff0-9287-4d99-b86f-1aa7f1731ad2", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "09a23a89-d6e1-4b37-9770-96bbe87560b8", "node_type": "4", "metadata": {}, "hash": "8ed8b399e332a627c77e064d3560935e93140a2139fd67fe76fbe492efed57dd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"The purpose of the National Health Interview Survey (NHIS) is to obtain information about the amount and distribution of illness, its effects in terms of disability and chronic impairments, and the kinds of health services people receive. Implementation of a redesigned NHIS, consisting of a basic module, a periodic module, and a topical module, began in 1997 (see NATIONAL HEALTH INTERVIEW SURVEY, 1997 [ICPSR 2954]). The 2007 NHIS contains the Household, Family, Person, Sample Adult, and Sample Child files from the basic module. Each record in Part 1, Household Level, contains data on type of living quarters, number of families in the household responding and not responding, and the month and year of the interview for each sampling unit. Part 2, Family Level, is made up of reconstructed variables from the person-level data of the basic module and includes information on sex, age, race, marital status, Hispanic origin, education, veteran", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 951, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f23c8bb0-7732-42c2-94ce-bec01b30ab41": {"__data__": {"id_": "f23c8bb0-7732-42c2-94ce-bec01b30ab41", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bab6e1af-7013-497b-984a-62fbc119b94b", "node_type": "4", "metadata": {}, "hash": "e807e3ce7f61074df0e896efa040484771c7da09fa6522fe23b90ab3e404e0cc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "status, family income, family size, major activities, health status, activity limits, and employment status, along with industry and occupation. As part of the basic module, Part 3, Person Level, provides information on all family members with respect to health status, limitation of daily activities, cognitive impairment, and health conditions. Also included are data on years at current residence, region variables, height, weight, bed days, doctor visits, hospital stays, and health care access and utilization. A randomly-selected adult in each family was interviewed for Part 4, Sample Adult, regarding respiratory conditions, use of nasal sp ray, renal conditions, AIDS, joint symptoms, health status, limitation of daily activities, and behaviors such as smoking, alcohol consumption, and physical activity in addition to questions regarding stroke, diabetes, arthritis, and weight control. Part 5, Sample Child, provides information from an adult in the household on medical conditions of one child in the household, such as", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1033, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4b33678c-d8c5-4162-ac14-b3ced1d0cce8": {"__data__": {"id_": "4b33678c-d8c5-4162-ac14-b3ced1d0cce8", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fad18478-0f39-4f3c-a26c-6e7417c6bc30", "node_type": "4", "metadata": {}, "hash": "45577b3811caa5b892d38c7a2cd9eaec1231cd86c3c5ccb35a72443bf2a70ca9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "respiratory problems, seizures, allergies, and use of special equipment like hearing aids, braces, or wheelchairs. Also included are variables regarding child behavior, the use of mental health services, and Attention Deficit Hyperactivity Disorder (ADHD), as well as responses to the SDQ, the Strengths and Difficulties questionnaire on child mental health. The 2007 data contain the Child Conditions - Limitation of Activity and Health Status (CHS), Child Health Care Access and Utilization (CAU), Child Mental Health Brief (CMB), Child Mental Health Services (CMS) and Child Influenza Immunization (CFI) sections. Part 6, Injury/Poison Episode, is an episode-based file that contains information about the external cause and nature of the injury or poisoning episode and what the person was doing at the time of the injury or poisoning episode, in addition to the date and place of occurrence. Part 7, Injury/Poison Episode Verbatim, contains edited narrative text descriptions of the injury or poisoning,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1008, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cca9fd02-6789-4746-abab-e1a79d930cc7": {"__data__": {"id_": "cca9fd02-6789-4746-abab-e1a79d930cc7", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bca5d914-8363-4775-aa79-0dbcf482ef98", "node_type": "4", "metadata": {}, "hash": "16b6cafec4a65ba8bb057510bc036b959b14296729f5efaf9e6baed6ff3dd142", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "provided by the respondent. Part 8, Adult Complementary and Alternative Medicine, and Part 9, Child Complementary and Alternative Medicine, provide information regarding the use of 17 nonconventional health care practices, including acupuncture, movement therapies, and relaxation techniques, for sample adults and sample children, respectively. Supplemental Sample Child, Part 10, and Supplemental Sample Child Alternative Medicine, Part 11, are supplemental files for the 2007 data release. These files provide dummy records to fill in the missing information for Part 5, Sample Child, and Part 9, Child Complementary and Alternative Medicine. Part 12, Paradata, does not contain health related information, but rather data which are related to the interview process, including measures of time, contact-ability, and cooperation. RAT_CAT3 Update, Part 13, corrects an error in the 2007 Family Level variable RAT_CAT3.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 921, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e64b2b10-79c9-4498-b5fc-b5257c6102ef": {"__data__": {"id_": "e64b2b10-79c9-4498-b5fc-b5257c6102ef", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0718ecd1-aaa4-4496-b175-b691c8ec8833", "node_type": "4", "metadata": {}, "hash": "ccb0b9709e0402a96e94117eea359f72708368848ba370c784e770fa7161eefd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"INVOLVED IN endosome to lysosome transport (ortholog); G protein-coupled receptor catabolic process (ortholog); ASSOCIATED WITH decreased vertical activity; impaired behavioral response to cocaine; ASSOCIATED WITH autistic disorder (ortholog); intellectual disability (ortholog); syndromic X-linked intellectual disability Lubs type (ortholog); FOUND IN cytoplasm (ortholog); cytosol (ortholog); nucleus (ortholog); INTERACTS WITH (S)-nicotine; 17alpha-ethynylestradiol; 2,3,7,8-tetrachlorodibenzodioxine\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 508, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8b179273-dbca-4a7b-bd6f-b91ea559c337": {"__data__": {"id_": "8b179273-dbca-4a7b-bd6f-b91ea559c337", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0a8126e6-ef15-4069-9014-9377e77bd8db", "node_type": "4", "metadata": {}, "hash": "49c557208e90e8debc0b40b0dd9ec6e980f1f3071fa1f4a014783b76ddc7772d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ENCODES a protein that exhibits nucleotide phosphatase activity, acting on free nucleotides (ortholog); phosphatase activity (ortholog); polynucleotide 5'-phosphatase activity (ortholog); INVOLVED IN polynucleotide 5' dephosphorylation (ortholog); protein dephosphorylation (ortholog); RNA metabolic process (ortholog); FOUND IN fibrillar center (ortholog); intercellular bridge (ortholog); nuclear speck (ortholog); INTERACTS WITH (S)-nicotine; 2,3,7,8-tetrachlorodibenzodioxine; 4,4'-diaminodiphenylmethane\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 512, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "366c7e0d-b386-459b-8f55-22adb0967d30": {"__data__": {"id_": "366c7e0d-b386-459b-8f55-22adb0967d30", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8e6ff787-6761-4b6a-b47e-a803bb22633f", "node_type": "4", "metadata": {}, "hash": "7d30d8af654cd292a28d587b0a881163dc122757507a7c6adf2b1f3dd52ed422", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"A series of phenanthroquinolizidine alkaloids 1\u201324 were prepared and first evaluated for their antiviral activity against tobacco mosaic virus (TMV). The bioassay results showed that most of these compounds exhibited good to excellent in vivo anti-TMV activity, of which compounds 1, 2, 15 and 16 displayed significantly higher activity than (R)-antofine and commercial Ningnanmycin at the same test condition. The substituents on the phenanthrene moiety play an important role for maintaining high in vivo antiviral activity. The introduction of 6-hydroxyl, which is proposed to interact with TMV RNA, did increased anti-TMV activity. The 14aR-configuration was confirmed to be the preferred antiviral configuration for phenanthroquinolizidine alkaloids. Introduction of hydroxy group at 15-position of phenanthroquinolizidine alkaloids increased activity for S-configuration but decreased activity for R-configuration. Present study provides fundamental support for development and optimization of phenanthroquinolizidine alkaloids as potential inhibitors of plant virus.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1077, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "75c59af7-e82e-437a-9c8a-bc6809ece297": {"__data__": {"id_": "75c59af7-e82e-437a-9c8a-bc6809ece297", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a2fb9a64-965e-44fc-b82c-f8bb58aed32c", "node_type": "4", "metadata": {}, "hash": "bb11de061acc93bd5ee3a4de8c3e86dfad35219cc09e145861b10cc218e7b320", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Post-weaning diarrhea (PWD) in piglets is a major problem in piggeries worldwide and results in severe economic losses. Infection with Enterotoxigenic Escherichia coli (ETEC) is the key culprit for the PWD disease. F4 fimbriae of ETEC are highly stable proteinaceous polymers, mainly composed of the major structural subunit FaeG, with a capacity to evoke mucosal immune responses, thus demonstrating a potential to act as an oral vaccine against ETEC-induced porcine PWD. In this study we used a transplastomic approach in tobacco to produce a recombinant variant of the FaeG protein, rFaeGntd/dsc, engineered for expression as a stable monomer by N-terminal deletion and donor strand-complementation (ntd/dsc). The generated transplastomic tobacco plants accumulated up to 2.0 g rFaeGntd/dsc per 1 kg fresh leaf tissue (more than 1% of dry leaf tissue) and showed normal phenotype indistinguishable from wild type untransformed plants. We determined that chloroplast-produced rFaeGntd/dsc protein retained the key properties of", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1031, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c3ebf273-b0c3-4eb0-833f-305089a7abf5": {"__data__": {"id_": "c3ebf273-b0c3-4eb0-833f-305089a7abf5", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "626fd3ce-52cf-46df-bd55-c7979f3387b5", "node_type": "4", "metadata": {}, "hash": "972d1e2628584835aa42735c64eae9f93f9bdb6ab0a95c631a95b9d343ede40d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "an oral vaccine, i.e. binding to porcine intestinal F4 receptors (F4R), and inhibition of the F4-possessing (F4+) ETEC attachment to F4R. Additionally, the plant biomass matrix was shown to delay degradation of the chloroplast-produced rFaeGntd/dsc in gastrointestinal conditions, demonstrating a potential to function as a shelter-vehicle for vaccine delivery. These results suggest that transplastomic plants expressing the rFaeGntd/dsc protein could be used for production and, possibly, delivery of an oral vaccine against porcine F4+ ETEC infections. Our findings therefore present a feasible approach for developing an oral vaccination strategy against porcine PWD.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 673, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "94b717cf-0e7a-4af1-b02e-5d896e9ee8ff": {"__data__": {"id_": "94b717cf-0e7a-4af1-b02e-5d896e9ee8ff", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "69c3357b-940f-4cf6-98b1-0ffc12680b76", "node_type": "4", "metadata": {}, "hash": "eb29027318d16cc63317c63a3a8d4a634efdb9eaffedea310666ab25c94f9ab0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Fusion protein strategies are useful tools to enhance expression and to support the development of purification technologies. The capacity of fusion protein strategies to enhance expression was explored in tobacco leaves and seeds. C-terminal fusion of elastin-like polypeptides (ELP) to influenza hemagglutinin under the control of either the constitutive CaMV 35S or the seed-specific USP promoter resulted in increased accumulation in both leaves and seeds compared to the unfused hemagglutinin. The addition of a hydrophobin to the C-terminal end of hemagglutinin did not significantly increase the expression level. We show here that, depending on the target protein, both hydrophobin fusion and ELPylation combined with endoplasmic reticulum (ER) targeting induced protein bodies in leaves as well as in seeds. The N-glycosylation pattern indicated that KDEL sequence-mediated retention of leaf-derived hemagglutinins and hemagglutinin-hydrophobin fusions were not completely retained in the ER. In contrast, hemagglutinin-ELP from leaves contained only the oligomannose form, suggesting", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1095, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a321271c-f947-439f-92ee-2f91623939d3": {"__data__": {"id_": "a321271c-f947-439f-92ee-2f91623939d3", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d00cd52c-48dc-458b-9461-63bed191d1e9", "node_type": "4", "metadata": {}, "hash": "2232b6df5d425dad2519eb811a3bcc706a7771f6168a237855ec117840ea5b40", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "complete ER retention. In seeds, ER retention seems to be nearly complete for all three constructs. An easy and scalable purification method for ELPylated proteins using membrane-based inverse transition cycling could be applied to both leaf- and seed-expressed hemagglutinins.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 279, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a1aafc7c-c342-4a1c-8039-9e471d8caaae": {"__data__": {"id_": "a1aafc7c-c342-4a1c-8039-9e471d8caaae", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fb58b84b-0bc3-47a0-b8be-951afaf2f4d6", "node_type": "4", "metadata": {}, "hash": "2f01efb1793fdd7312a26f29be41155858a6239dfbba2a80117b2b60ce91a7f9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Background\\nTobacco dependence is the leading cause of preventable death and disabilities worldwide and nicotine is the main substance responsible for the addiction to tobacco. A vaccine against nicotine was tested in a 6-month randomized, double blind phase II smoking cessation study in 341 smokers with a subsequent 6-month follow-up period.\\nMethodology/Principal Findings\\n229 subjects were randomized to receive five intramuscular injections of the nicotine vaccine and 112 to receive placebo at monthly intervals. All subjects received individual behavioral smoking cessation counseling. The vaccine was safe, generally well tolerated and highly immunogenic, inducing a 100% antibody responder rate after the first injection. Point prevalence of abstinence at month 2 showed a statistically significant difference between subjects treated with Nicotine-Q\u03b2 (47.2%) and placebo (35.1%) (P = 0.036), but continuous abstinence between months 2 and 6 was not significantly different. However, in subgroup analysis of the per-protocol population, the third of subjects with highest antibody", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1093, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bfbf5b89-632f-4a9d-a345-fe1a37b01dbf": {"__data__": {"id_": "bfbf5b89-632f-4a9d-a345-fe1a37b01dbf", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f76c1a1d-6034-4baa-9a23-b67b5202f40e", "node_type": "4", "metadata": {}, "hash": "17385c6ff3fad6dc669e9faa4a1fb92ea2894afa4cdfae9e3d227da14736ba8a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "levels showed higher continuous abstinence from month 2 until month 6 (56.6%) than placebo treated participants (31.3%) (OR 2.9; P = 0.004) while medium and low antibody levels did not increase abstinence rates. After 12 month, the difference in continuous abstinence rate between subjects on placebo and those with high antibody response was maintained (difference 20.2%, P = 0.012).\\nConclusions\\nWhereas Nicotine-Q\u03b2 did not significantly increase continuous abstinence rates in the intention-to-treat population, subgroup analyses of the per-protocol population suggest that such a vaccination against nicotine can significantly increase continuous abstinence rates in smokers when sufficiently high antibody levels are achieved. Immunotherapy might open a new avenue to the treatment of nicotine addiction.\\nTrial Registration\\nSwiss Medical Registry 2003DR2327; ClinicalTrials.gov NCT00369616\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 899, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9c434ab9-2e36-49dc-ab3d-ade85752eabe": {"__data__": {"id_": "9c434ab9-2e36-49dc-ab3d-ade85752eabe", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3efc6a40-a67d-4302-8a96-b5b6fc28415b", "node_type": "4", "metadata": {}, "hash": "0156db1beb742138f7e31c96bafe9c68e55a587948192f1d44d021130ef4f097", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ENCODES a protein that exhibits nucleic acid binding (inferred); RNA binding (inferred); ASSOCIATED WITH autistic disorder (ortholog); genetic disease (ortholog); Mental Retardation, X-Linked, Syndromic, Bain Type (ortholog); FOUND IN cytosol (ortholog); nucleoplasm (ortholog); postsynaptic density (ortholog); INTERACTS WITH (S)-nicotine; 17alpha-ethynylestradiol; Aroclor 1254\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 383, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4a09fc11-5a5d-45e4-a172-cee625ba4634": {"__data__": {"id_": "4a09fc11-5a5d-45e4-a172-cee625ba4634", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "64402d25-895d-45d9-9695-c3c7ae6162fe", "node_type": "4", "metadata": {}, "hash": "24db812e12c54e8be49f2f524688fd5f267d87d41ef5e0d3e53420008d9a853a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Involved in autophagosome assembly. Localizes to the endoplasmic reticulum membrane. INVOLVED IN autophagosome assembly; FOUND IN endoplasmic reticulum membrane; INTERACTS WITH (S)-nicotine; 3-isobutyl-1-methyl-7H-xanthine; 4,4'-sulfonyldiphenol\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 249, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d2c45121-255c-4a44-86f2-956425f569a4": {"__data__": {"id_": "d2c45121-255c-4a44-86f2-956425f569a4", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3ce22e43-adb2-43cb-bd8a-67ffc57caefc", "node_type": "4", "metadata": {}, "hash": "ee2ea7dc33a7dc09a37cb1fe85453cbb1811737878d15cebdc0e3bde89e48d75", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Pulmonary accumulation of neutrophils is typical for active smokers who are also predisposed to multiple inflammatory and infectious lung diseases. We show that human neutrophil exposure to cigarette smoke extract (CSE) leads to an atypical cell death sharing features of apoptosis, autophagy and necrosis. Accumulation of tar-like substances in autophagosomes is also apparent. Before detection of established cell death markers, CSE-treated neutrophils are effectively recognized and non-phlogistically phagocytosed by monocyte-derived macrophages. Blockade of LOX-1 and scavenger receptor A, but not MARCO or CD36, as well as pre-incubation with oxLDL, inhibited phagocytosis, suggesting that oxLDL-like structures are major phagocytosis signals. Specific lipid (\\\\beta-carotene and quercetin), but not aqueous, antioxidants increased the pro-phagocytic effects of CSE. In contrast to non-phlogistic phagocytosis, degranulation of secondary granules, as monitored by lactoferrin release, was apparent on CSE exposure, which is likely to promote pulmonary inflammation and tissue degradation. Furthermore, CSE-exposed neutrophils exhibited a compromised ability", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1165, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cb1f88e3-072f-428a-877e-df0892599412": {"__data__": {"id_": "cb1f88e3-072f-428a-877e-df0892599412", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ce3cb6ab-8fbe-4b47-99d2-8c5ba4e19a7d", "node_type": "4", "metadata": {}, "hash": "a92c9a3d1b0c5d63a5c7929ef490531f733f454ad96ba078eb103af00795da8e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "to ingest the respiratory pathogen, Staphylococcus aureus, which likely contributes to bacterial persistence in the lungs of smokers and is likely to promote further pulmonary recruitment of neutrophils. These data provide mechanistic insight into the lack of accumulation of apoptotic neutrophil populations in the lungs of smokers and their increased susceptibility to degradative pulmonary diseases and bacterial infections.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 429, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c458f722-7c61-4af9-b72a-95e11791d4aa": {"__data__": {"id_": "c458f722-7c61-4af9-b72a-95e11791d4aa", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5f30f38c-7a63-4baf-89f3-6b75728d8ea4", "node_type": "4", "metadata": {}, "hash": "49c557208e90e8debc0b40b0dd9ec6e980f1f3071fa1f4a014783b76ddc7772d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ENCODES a protein that exhibits nucleotide phosphatase activity, acting on free nucleotides (ortholog); phosphatase activity (ortholog); polynucleotide 5'-phosphatase activity (ortholog); INVOLVED IN polynucleotide 5' dephosphorylation (ortholog); protein dephosphorylation (ortholog); RNA metabolic process (ortholog); FOUND IN fibrillar center (ortholog); intercellular bridge (ortholog); nuclear speck (ortholog); INTERACTS WITH (S)-nicotine; 2,3,7,8-tetrachlorodibenzodioxine; 4,4'-diaminodiphenylmethane\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 512, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cededcaa-1d1b-4458-ae93-b826a08204b2": {"__data__": {"id_": "cededcaa-1d1b-4458-ae93-b826a08204b2", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "92e960f6-092d-479b-aa01-55aec4130a70", "node_type": "4", "metadata": {}, "hash": "5cf459d41a017dc6c258e70e03b3dcc873d8c90fa0622b60dc67f8503484445e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ENCODES a protein that exhibits protein C-terminus binding; ASSOCIATED WITH 1q24 Deletion Syndrome; FOUND IN cytosol; INTERACTS WITH (S)-nicotine; 17beta-estradiol; 3-isobutyl-1-methyl-7H-xanthine\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 200, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "497c5bb0-0c83-4751-95ab-56103e2df367": {"__data__": {"id_": "497c5bb0-0c83-4751-95ab-56103e2df367", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a8c94450-1b41-4e27-b5da-497cc15d07fc", "node_type": "4", "metadata": {}, "hash": "7ebb13fd7626437ac5a59b67304f0bed5a70b7600482cc2f03fd32dd866d64d4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Exhibits protein C-terminus binding activity. Predicted to be involved in hematopoietic progenitor cell differentiation. Localizes to the cytosol. ENCODES a protein that exhibits protein C-terminus binding; ASSOCIATED WITH 1q24 Deletion Syndrome; FOUND IN cytosol; INTERACTS WITH (S)-nicotine; 17beta-estradiol; 3-isobutyl-1-methyl-7H-xanthine\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 347, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0c755704-3f45-4582-8f2d-9b09fd836ae6": {"__data__": {"id_": "0c755704-3f45-4582-8f2d-9b09fd836ae6", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f6ae0ff4-9c4f-4870-952a-efb73935703d", "node_type": "4", "metadata": {}, "hash": "d9e5304c87e2faf71ed14f849c6f743bc6a893bf9c9bc4222085fd3a24fc2267", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ASSOCIATED WITH Cerebral Visual Impairment and Intellectual Disability (ortholog); INTERACTS WITH (S)-nicotine (ortholog); 2,3,7,8-tetrachlorodibenzodioxine (ortholog); 4,4'-diaminodiphenylmethane (ortholog)\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 211, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "76eee6fc-ca4b-4b6b-ae7f-e076b2edc5b6": {"__data__": {"id_": "76eee6fc-ca4b-4b6b-ae7f-e076b2edc5b6", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9b6e527d-f83b-4095-848f-44ea0803e244", "node_type": "4", "metadata": {}, "hash": "2f01efb1793fdd7312a26f29be41155858a6239dfbba2a80117b2b60ce91a7f9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Background\\nTobacco dependence is the leading cause of preventable death and disabilities worldwide and nicotine is the main substance responsible for the addiction to tobacco. A vaccine against nicotine was tested in a 6-month randomized, double blind phase II smoking cessation study in 341 smokers with a subsequent 6-month follow-up period.\\nMethodology/Principal Findings\\n229 subjects were randomized to receive five intramuscular injections of the nicotine vaccine and 112 to receive placebo at monthly intervals. All subjects received individual behavioral smoking cessation counseling. The vaccine was safe, generally well tolerated and highly immunogenic, inducing a 100% antibody responder rate after the first injection. Point prevalence of abstinence at month 2 showed a statistically significant difference between subjects treated with Nicotine-Q\u03b2 (47.2%) and placebo (35.1%) (P = 0.036), but continuous abstinence between months 2 and 6 was not significantly different. However, in subgroup analysis of the per-protocol population, the third of subjects with highest antibody", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1093, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6bc1f391-39aa-4fc8-b3dc-07271ddec689": {"__data__": {"id_": "6bc1f391-39aa-4fc8-b3dc-07271ddec689", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "575791d3-021b-4569-9de9-d1b0afdcdf0d", "node_type": "4", "metadata": {}, "hash": "17385c6ff3fad6dc669e9faa4a1fb92ea2894afa4cdfae9e3d227da14736ba8a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "levels showed higher continuous abstinence from month 2 until month 6 (56.6%) than placebo treated participants (31.3%) (OR 2.9; P = 0.004) while medium and low antibody levels did not increase abstinence rates. After 12 month, the difference in continuous abstinence rate between subjects on placebo and those with high antibody response was maintained (difference 20.2%, P = 0.012).\\nConclusions\\nWhereas Nicotine-Q\u03b2 did not significantly increase continuous abstinence rates in the intention-to-treat population, subgroup analyses of the per-protocol population suggest that such a vaccination against nicotine can significantly increase continuous abstinence rates in smokers when sufficiently high antibody levels are achieved. Immunotherapy might open a new avenue to the treatment of nicotine addiction.\\nTrial Registration\\nSwiss Medical Registry 2003DR2327; ClinicalTrials.gov NCT00369616\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 899, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "367b9265-b730-44a3-9149-8b4661346844": {"__data__": {"id_": "367b9265-b730-44a3-9149-8b4661346844", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "af5a7a84-a0ba-4ac0-8ea8-36502e81ccbe", "node_type": "4", "metadata": {}, "hash": "49c557208e90e8debc0b40b0dd9ec6e980f1f3071fa1f4a014783b76ddc7772d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ENCODES a protein that exhibits nucleotide phosphatase activity, acting on free nucleotides (ortholog); phosphatase activity (ortholog); polynucleotide 5'-phosphatase activity (ortholog); INVOLVED IN polynucleotide 5' dephosphorylation (ortholog); protein dephosphorylation (ortholog); RNA metabolic process (ortholog); FOUND IN fibrillar center (ortholog); intercellular bridge (ortholog); nuclear speck (ortholog); INTERACTS WITH (S)-nicotine; 2,3,7,8-tetrachlorodibenzodioxine; 4,4'-diaminodiphenylmethane\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 512, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "adac1fbd-1731-43ee-81b7-883f8f6d7b16": {"__data__": {"id_": "adac1fbd-1731-43ee-81b7-883f8f6d7b16", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "045b78b1-9c84-4a29-8bf7-64c94e60e9be", "node_type": "4", "metadata": {}, "hash": "38d8c3e53b1fd2b82290f7de62bf44159e3bbeebf5f587f29ec7c77db552ae05", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ASSOCIATED WITH arteriosclerosis (ortholog); Chemical and Drug Induced Liver Injury (ortholog); Parkinson's disease (ortholog); INTERACTS WITH (S)-nicotine; 1-chloro-2,4-dinitrobenzene; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 234, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7ad3c40f-09b7-4de9-b8e3-90ae703d13e8": {"__data__": {"id_": "7ad3c40f-09b7-4de9-b8e3-90ae703d13e8", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3c86e01d-19ee-4dde-bd3d-07fda3d2da7a", "node_type": "4", "metadata": {}, "hash": "3a73eb66788bbf4516e6523f790911a85993a909eb1e6d1ce8099ebd316be55f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"<p>The purpose of the National Health Interview Survey (NHIS)\\nis to obtain information about the amount and distribution of illness,\\nits effects in terms of disability and chronic impairments, and the\\nkinds of health services people receive. Implementation of a\\nredesigned NHIS, consisting of a basic module, a periodic module, and\\na topical module, began in 1997 (See NATIONAL HEALTH INTERVIEW SURVEY,\\n1997 [ICPSR 2954]).</p> <p>The 2001 NHIS contains the Household, Family,\\nPerson, Sample Adult, Sample Child, Child Immunization, and Injury and\\nPoison Episode data files from the basic module. Each record in the\\nHousehold-Level File (Part 1) contains data on type of living\\nquarters, number of families in the household responding and not\\nresponding, and the month and year of the interview for each sampling\\nunit.</p>\\n<p>The Family-Level File (Part 2) is made up of reconstructed\\nvariables from the person-level data of the basic module and includes\\ninformation on sex, age, race, marital status, Hispanic origin,\\neducation, veteran status, family income, family size, major\\nactivities, health", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1116, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "93cbeb7b-8704-426a-89b2-c998e3a7632b": {"__data__": {"id_": "93cbeb7b-8704-426a-89b2-c998e3a7632b", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7570211d-85c8-49da-99e1-dc3f037d83f4", "node_type": "4", "metadata": {}, "hash": "f4ed3a8f8784414a5cebcd82bcc1241300decdf95ad9b20a3165fb4da4367def", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "status, activity limits, and employment status,\\nalong with industry and occupation.</p> <p>As part of the basic module, the\\nPerson-Level File (Part 3) provides information on all family members\\nwith respect to health status, limitation of daily activities,\\ncognitive impairment, and health conditions. Also included are data on\\nyears at current residence, region variables, height, weight, bed\\ndays, doctor visits, hospital stays, and health care access and\\nutilization.</p> <p>A randomly-selected adult in each family was interviewed\\nfor the Sample Adult File (Part 4) regarding respiratory conditions,\\nrenal conditions, AIDS, joint symptoms, health status, limitation of\\ndaily activities, and behaviors such as smoking, alcohol consumption,\\nand physical activity. Also included in this file are variables\\npertaining to the Healthy People 2010 Objectives.</p> <p>The Sample Child\\nFile (Part 5) provides information from an adult in the household on\\nmedical conditions of one child in the household, such as respiratory\\nproblems, seizures, allergies, and use of special equipment such as\\nhearing aids, braces, or wheelchairs. Also included are variables\\nregarding child", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1186, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "82e83df3-1a02-41f0-8348-0f2521b29db2": {"__data__": {"id_": "82e83df3-1a02-41f0-8348-0f2521b29db2", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6bfa7dcd-dc94-4b23-9257-141945c3cb48", "node_type": "4", "metadata": {}, "hash": "d90aed061e70c1fbca7992276041e97ec4b583c93ceb5b97f40dc9f80e017b23", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "behavior, the use of mental health services, and\\nAttention Deficit Hyperactivity Disorder (ADHD).</p> <p>The Child\\nImmunization File (Part 6) presents information from shot records and\\nsupplies vaccination status, along with the number and dates of shots,\\nand information about the chicken pox vaccine.</p> <p>Episode-based\\ninformation regarding injuries and poisonings are found in the Injury\\nand Poison Episode File (Part 7), which examines the cause and date of\\ninjury or poisoning, loss of time from work or school, and whether the\\nepisode resulted in hospitalization.</p> <p>Information in the Injury and\\nPoison Verbatim File (Part 8) is comprised of narrative text\\ndescribing injuries, including type of injury, how the injury\\noccurred, and the body part injured.</p>\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 786, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d774b46c-11d7-4ecb-850f-8d88a02d8b57": {"__data__": {"id_": "d774b46c-11d7-4ecb-850f-8d88a02d8b57", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "463d7c25-6d92-4c5c-8eee-9cc27fb0bd6e", "node_type": "4", "metadata": {}, "hash": "3a73eb66788bbf4516e6523f790911a85993a909eb1e6d1ce8099ebd316be55f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"<p>The purpose of the National Health Interview Survey (NHIS)\\nis to obtain information about the amount and distribution of illness,\\nits effects in terms of disability and chronic impairments, and the\\nkinds of health services people receive. Implementation of a\\nredesigned NHIS, consisting of a basic module, a periodic module, and\\na topical module, began in 1997 (See NATIONAL HEALTH INTERVIEW SURVEY,\\n1997 [ICPSR 2954]).</p> <p>The 2001 NHIS contains the Household, Family,\\nPerson, Sample Adult, Sample Child, Child Immunization, and Injury and\\nPoison Episode data files from the basic module. Each record in the\\nHousehold-Level File (Part 1) contains data on type of living\\nquarters, number of families in the household responding and not\\nresponding, and the month and year of the interview for each sampling\\nunit.</p>\\n<p>The Family-Level File (Part 2) is made up of reconstructed\\nvariables from the person-level data of the basic module and includes\\ninformation on sex, age, race, marital status, Hispanic origin,\\neducation, veteran status, family income, family size, major\\nactivities, health", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1116, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ce86acb4-4045-4b65-9c14-2d460df29c9e": {"__data__": {"id_": "ce86acb4-4045-4b65-9c14-2d460df29c9e", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a6692b3f-56dd-4ef4-844c-31bac5698b03", "node_type": "4", "metadata": {}, "hash": "f4ed3a8f8784414a5cebcd82bcc1241300decdf95ad9b20a3165fb4da4367def", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "status, activity limits, and employment status,\\nalong with industry and occupation.</p> <p>As part of the basic module, the\\nPerson-Level File (Part 3) provides information on all family members\\nwith respect to health status, limitation of daily activities,\\ncognitive impairment, and health conditions. Also included are data on\\nyears at current residence, region variables, height, weight, bed\\ndays, doctor visits, hospital stays, and health care access and\\nutilization.</p> <p>A randomly-selected adult in each family was interviewed\\nfor the Sample Adult File (Part 4) regarding respiratory conditions,\\nrenal conditions, AIDS, joint symptoms, health status, limitation of\\ndaily activities, and behaviors such as smoking, alcohol consumption,\\nand physical activity. Also included in this file are variables\\npertaining to the Healthy People 2010 Objectives.</p> <p>The Sample Child\\nFile (Part 5) provides information from an adult in the household on\\nmedical conditions of one child in the household, such as respiratory\\nproblems, seizures, allergies, and use of special equipment such as\\nhearing aids, braces, or wheelchairs. Also included are variables\\nregarding child", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1186, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0a569a32-4af5-468b-9e3f-8bdc251131e3": {"__data__": {"id_": "0a569a32-4af5-468b-9e3f-8bdc251131e3", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5ccfc505-d8c2-43ad-817e-e36d7300b179", "node_type": "4", "metadata": {}, "hash": "d90aed061e70c1fbca7992276041e97ec4b583c93ceb5b97f40dc9f80e017b23", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "behavior, the use of mental health services, and\\nAttention Deficit Hyperactivity Disorder (ADHD).</p> <p>The Child\\nImmunization File (Part 6) presents information from shot records and\\nsupplies vaccination status, along with the number and dates of shots,\\nand information about the chicken pox vaccine.</p> <p>Episode-based\\ninformation regarding injuries and poisonings are found in the Injury\\nand Poison Episode File (Part 7), which examines the cause and date of\\ninjury or poisoning, loss of time from work or school, and whether the\\nepisode resulted in hospitalization.</p> <p>Information in the Injury and\\nPoison Verbatim File (Part 8) is comprised of narrative text\\ndescribing injuries, including type of injury, how the injury\\noccurred, and the body part injured.</p>\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 786, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "079244c3-02cc-46fa-93aa-afbe0af52da7": {"__data__": {"id_": "079244c3-02cc-46fa-93aa-afbe0af52da7", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9a4862c0-2c36-41df-8ad4-981878441600", "node_type": "4", "metadata": {}, "hash": "2faa334d2dbd39f7a01f01c1388864e6005a88d0862d6512cd269971e5dc42a8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"The purpose of the National Health Interview Survey (NHIS) is to obtain information about the amount and distribution of illness, its effects in terms of disability and chronic impairments, and the kinds of health services people receive. Implementation of a redesigned NHIS, consisting of a basic module, a periodic module, and a topical module, began in 1997 (See NATIONAL HEALTH INTERVIEW SURVEY, 1997 [ICPSR 2954]). The 2001 NHIS contains the Household, Family, Person, Sample Adult, Sample Child, Child Immunization, and Injury and Poison Episode data files from the basic module. Each record in the Household-Level File (Part 1) contains data on type of living quarters, number of families in the household responding and not responding, and the month and year of the interview for each sampling unit. The Family-Level File (Part 2) is made up of reconstructed variables from the person-level data of the basic module and includes information on", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 953, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a184d45a-d98f-4f7e-9938-9e41199ecaaf": {"__data__": {"id_": "a184d45a-d98f-4f7e-9938-9e41199ecaaf", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0c072d0a-6a98-4e1a-a7cd-79b9c71589ad", "node_type": "4", "metadata": {}, "hash": "f51f31a02bfe62caa04890d9b19796c550510ac2e243cbbf97d02ee614e86c80", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "sex, age, race, marital status, Hispanic origin, education, veteran status, family income, family size, major activities, health status, activity limits, and employment status, along with industry and occupation. As part of the basic module, the Person-Level File (Part 3) provides information on all family members with respect to health status, limitation of daily activities, cognitive impairment, and health conditions. Also included are data on years at current residence, region variables, height, weight, bed days, doctor visits, hospital stays, and health care access and utilization. A randomly-selected adult in each family was interviewed for the Sample Adult File (Part 4) regarding respiratory conditions, renal conditions, AIDS, joint symptoms, health status, limitation of daily activities, and behaviors such as smoking, alcohol consumption, and physical activity. Also included in this file are variables pertaining to the Healthy People 2010 Objectives. The Sample Child File (Part 5) provides information from an adult in the", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1044, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e49072e5-34cd-4298-b0a8-abdf58853728": {"__data__": {"id_": "e49072e5-34cd-4298-b0a8-abdf58853728", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6fd149d8-f196-4892-abae-fe698f01916a", "node_type": "4", "metadata": {}, "hash": "6d3a2f5ab27c6e3b26707ebae0723db6b97ac39c1456e81c280578fadfece70f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "household on medical conditions of one child in the household, such as respiratory problems, seizures, allergies, and use of special equipment such as hearing aids, braces, or wheelchairs. Also included are variables regarding child behavior, the use of mental health services, and Attention Deficit Hyperactivity Disorder (ADHD). The Child Immunization File (Part 6) presents information from shot records and supplies vaccination status, along with the number and dates of shots, and information about the chicken pox vaccine. Episode-based information regarding injuries and poisonings are found in the Injury and Poison Episode File (Part 7), which examines the cause and date of injury or poisoning, loss of time from work or school, and whether the episode resulted in hospitalization. Information in the Injury and Poison Verbatim File (Part 8) is comprised of narrative text describing injuries, including type of injury, how the injury occurred, and the body part injured.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 983, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "95ccbbc2-0be8-4b3f-93c1-db7fa562be06": {"__data__": {"id_": "95ccbbc2-0be8-4b3f-93c1-db7fa562be06", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ed943ff1-0464-4398-bf7a-0d8fbbeca0d3", "node_type": "4", "metadata": {}, "hash": "2faa334d2dbd39f7a01f01c1388864e6005a88d0862d6512cd269971e5dc42a8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"The purpose of the National Health Interview Survey (NHIS) is to obtain information about the amount and distribution of illness, its effects in terms of disability and chronic impairments, and the kinds of health services people receive. Implementation of a redesigned NHIS, consisting of a basic module, a periodic module, and a topical module, began in 1997 (See NATIONAL HEALTH INTERVIEW SURVEY, 1997 [ICPSR 2954]). The 2001 NHIS contains the Household, Family, Person, Sample Adult, Sample Child, Child Immunization, and Injury and Poison Episode data files from the basic module. Each record in the Household-Level File (Part 1) contains data on type of living quarters, number of families in the household responding and not responding, and the month and year of the interview for each sampling unit. The Family-Level File (Part 2) is made up of reconstructed variables from the person-level data of the basic module and includes information on", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 953, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cb1a559b-f2dd-4eae-8171-484d192a10ba": {"__data__": {"id_": "cb1a559b-f2dd-4eae-8171-484d192a10ba", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c2a9410d-1021-4b1d-8e37-76dccb721b03", "node_type": "4", "metadata": {}, "hash": "f59e96987b3fd110082c56e77677326392bb8d050c8d9d08009c633e373a8c8c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "sex, age, race, marital status, Hispanic origin, education, veteran status, family income, family size, major activities, health status, activity limits, and employment status, along with industry and occupation. As part of the basic module, the Person-Level File (Part 3) provides information on all family members with respect to health status, limitation of daily activities, cognitive impairment, and health conditions. Also included are data on years at current residence, region v ariables, height, weight, bed days, doctor visits, hospital stays, and health care access and utilization. A randomly-selected adult in each family was interviewed for the Sample Adult File (Part 4) regarding respiratory conditions, renal conditions, AIDS, joint symptoms, health status, limitation of daily activities, and behaviors such as smoking, alcohol consumption, and physical activity. Also included in this file are variables pertaining to the Healthy People 2010 Objectives. The Sample Child File (Part 5) provides information from an adult in", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1041, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1d7b12b3-027e-4681-b378-f42125d6e048": {"__data__": {"id_": "1d7b12b3-027e-4681-b378-f42125d6e048", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c7c7a898-be6e-4468-8923-0f77a490f21b", "node_type": "4", "metadata": {}, "hash": "67bea5e767e0192a3f33200493f34539c6bc8918aa62e8d4988092c65e43971c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "the household on medical conditions of one child in the household, such as respiratory problems, seizures, allergies, and use of special equipment such as hearing aids, braces, or wheelchairs. Also included are variables regarding child behavior, the use of mental health services, and Attention Deficit Hyperactivity Disorder (ADHD). The Child Immunization File (Part 6) presents information from shot records and supplies vaccination status, along with the number and dates of shots, and information about the chicken pox vaccine. Episode-based information regarding injuries and poisonings are found in the Injury and Poison Episode File (Part 7), which examines the cause and date of injury or poisoning, loss of time from work or school, and whether the episode resulted in hospitalization. Information in the Injury and Poison Verbatim File (Part 8) is comprised of narrative text describing injuries, including type of injury, how the injury occurred, and the body part injured.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 987, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "eceb91ce-d5d1-4271-8c60-be68a824cad1": {"__data__": {"id_": "eceb91ce-d5d1-4271-8c60-be68a824cad1", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e6bdfe42-9113-47df-b54e-67412f7c081b", "node_type": "4", "metadata": {}, "hash": "f54d99c7ffd6bca5f56d97411ceb8c0a5ecb1813f0a0ad307581ddb997e38758", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Under a traditional paradigm, only those with the expected background knowledge consume academic literature. The lay press, as well as government and non-government agencies, play a complementary role of extracting findings of high interest or importance and translating them for general viewing. The need for accurate reporting and public advising is paramount when attempting to tackle epidemic outbreaks through behavior change. Yet, public trust in media outlets is at a historic low. The Crisis and Emergency Risk Communication (CERC) model for media reporting on public health emergencies was established in 2005 and has subsequently been used to analyze media reporting on outbreaks of influenza and measles as well as smoking habits and medication compliance. However, no media analysis had yet been performed on the 2013\u20132016 Ebola Virus Disease (EVD) outbreak. This study compared the EVD information relayed by lay press sources with general review articles in the academic literature through", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1005, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "58732b24-265a-4cdd-91ca-9f56d5b78e9e": {"__data__": {"id_": "58732b24-265a-4cdd-91ca-9f56d5b78e9e", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d7e62501-a8c4-4a6e-a73e-25a3c43e674e", "node_type": "4", "metadata": {}, "hash": "b2d7c155574ee8296b72d67083803c6ea8039dfc34e76a89a903bd9fb8604763", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "a mixed-methods analysis. These findings suggest that comprehensive review articles could not serve as a source to clarify and contextualize the uncertainties around the EVD outbreak, perhaps due to adherence to technical accuracy at the expense of clarity within the context of outbreak conditions. This finding does not imply inferiority of the academic literature, nor does it draw direct causation between confusion in review articles and public misunderstanding. Given the erosion of the barriers siloing academia, combined with the demands of today\u2019s fast-paced media environment, contemporary researchers should realize that no study is outside the public forum and to therefore consider shifting the paradigm to take personal responsibility in the process of accurately translating their scientific words into public policy actions to best serve as a source of clarity.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 879, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b276f0a5-a5cd-4b54-b22e-ce4bc66ffbd2": {"__data__": {"id_": "b276f0a5-a5cd-4b54-b22e-ce4bc66ffbd2", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d7bcf9d5-4a1a-4699-ba6c-bee2cdc9f4f2", "node_type": "4", "metadata": {}, "hash": "89e209c523efcdd081365d6f589ad70ee0dd9c2b771133ed74b2bdcec4bc6c40", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Source at: <a href=http://doi.org/10.1016/S0140-6736(17)32366-8> http://doi.org/10.1016/S0140-6736(17)32366-8 </a>\\n\\t\\t\\tBackground: <br> The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of risk factor exposure and attributable burden of disease. By providing estimates over a long time series, this study can monitor risk exposure trends critical to health surveillance and inform policy debates on the importance of addressing risks in context. <br>\\n\\t\\t\\t Methods: <br> We used the comparative risk assessment framework developed for previous iterations of GBD to estimate\\n\\t\\t\\t levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs), by age group,\\n\\t\\t\\t sex, year, and location for 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks\\n\\t\\t\\t from 1990 to 2016. This study included 481 risk-outcome pairs that met the GBD study criteria for convincing or\\n\\t\\t\\t probable evidence of causation. We extracted relative risk (RR) and exposure estimates from 22 717 randomised\\n\\t\\t\\t controlled", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1159, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a17965d4-a342-4265-976f-b35b406e58f4": {"__data__": {"id_": "a17965d4-a342-4265-976f-b35b406e58f4", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b6293498-5a80-4cd9-867a-a96a606120c7", "node_type": "4", "metadata": {}, "hash": "ab4ac652195b9a0ddc6d5bce4f4220951ac5c40bc9545ddff84f5bc729767aed", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "trials, cohorts, pooled cohorts, household surveys, census data, satellite data, and other sources, according\\n\\t\\t\\t to the GBD 2016 source counting methods. Using the counterfactual scenario of theoretical minimum risk exposure\\n\\t\\t\\t level (TMREL), we estimated the portion of deaths and DALYs that could be attributed to a given risk. Finally, we\\n\\t\\t\\t explored four drivers of trends in attributable burden: population growth, population ageing, trends in risk exposure,\\n\\t\\t\\t and all other factors combined. <br>\\n\\t\\t\\t Findings: <br> Since 1990, exposure increased significantly for 30 risks, did not change significantly for four risks, and\\n\\t\\t\\t decreased significantly for 31 risks. Among risks that are leading causes of burden of disease, child growth failure and\\n\\t\\t\\t household air pollution showed the most significant declines, while metabolic risks, such as body-mass index and high\\n\\t\\t\\t fasting plasma glucose, showed significant increases. In 2016, at Level 3 of the hierarchy, the three leading risk factors\\n\\t\\t\\t in terms of attributable DALYs", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1079, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ea739c0a-c962-407a-9659-53d0ffb709c5": {"__data__": {"id_": "ea739c0a-c962-407a-9659-53d0ffb709c5", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "86c69809-b181-46bf-97fb-cd56e19ce40a", "node_type": "4", "metadata": {}, "hash": "7fd708ed3ae22a9072a3b145dd9df237ce375a212cf2aa84a865007c904f4782", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "at the global level for men were smoking (124\u00b71 million DALYs [95% UI 111\u00b72 million to\\n\\t\\t\\t 137\u00b70 million]), high systolic blood pressure (122\u00b72 million DALYs [110\u00b73 million to 133\u00b73 million], and low birthweight\\n\\t\\t\\t and short gestation (83\u00b70 million DALYs [78\u00b73 million to 87\u00b77 million]), and for women, were high systolic blood\\n\\t\\t\\t pressure (89\u00b79 million DALYs [80\u00b79 million to 98\u00b72 million]), high body-mass index (64\u00b78 million DALYs [44\u00b74 million\\n\\t\\t\\t to 87\u00b76 million]), and high fasting plasma glucose (63\u00b78 million DALYs [53\u00b72 million to 76\u00b73 million]). In 2016 in\\n\\t\\t\\t 113 countries, the leading risk factor in terms of attributable DALYs was a metabolic risk factor. Smoking remained\\n\\t\\t\\t among the leading five risk factors for DALYs for 109 countries, while low birthweight and short gestation was the\\n\\t\\t\\t leading risk factor for DALYs in 38 countries, particularly in sub-Saharan Africa and South Asia. In terms of important\\n\\t\\t\\t drivers of change in trends of burden", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1005, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e36e1915-4716-4ec7-8263-9389511f550b": {"__data__": {"id_": "e36e1915-4716-4ec7-8263-9389511f550b", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ffc793a0-da1d-4e88-a2a1-51691fcf509a", "node_type": "4", "metadata": {}, "hash": "70064e5ad08c9962bcf4b6dbadbf1b9cf173f7a7da10541487b1ad08d29c1c4b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "attributable to risk factors, between 2006 and 2016 exposure to risks explains an\\n\\t\\t\\t 9\u00b73% (6\u00b79\u201311\u00b76) decline in deaths and a 10\u00b78% (8\u00b73\u201313\u00b71) decrease in DALYs at the global level, while population\\n\\t\\t\\t ageing accounts for 14\u00b79% (12\u00b77\u201317\u00b75) of deaths and 6\u00b72% (3\u00b79\u20138\u00b77) of DALYs, and population growth for 12\u00b74%\\n\\t\\t\\t (10\u00b71\u201314\u00b79) of deaths and 12\u00b74% (10\u00b71\u201314\u00b79) of DALYs. The largest contribution of trends in risk exposure to disease\\n\\t\\t\\t burden is seen between ages 1 year and 4 years, where a decline of 27\u00b73% (24\u00b79\u201329\u00b77) of the change in DALYs between\\n\\t\\t\\t 2006 and 2016 can be attributed to declines in exposure to risks. <br>\\n\\t\\t\\t Interpretation: <br> Increasingly detailed understanding of the trends in risk exposure and the RRs for each risk-outcome\\n\\t\\t\\t pair provide insights into both the magnitude of health loss attributable to risks and how modification of risk exposure\\n\\t\\t\\t has contributed to health trends. Metabolic risks warrant particular policy attention, due to", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1008, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "264dc903-d521-4dd9-8ad0-6d7be3478de9": {"__data__": {"id_": "264dc903-d521-4dd9-8ad0-6d7be3478de9", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "463571c9-bab0-44a7-a4c9-9782851b527a", "node_type": "4", "metadata": {}, "hash": "1b56b105e3625992e5b7814756cd9b6e22169693e4de4de7ecc850e9b5e33938", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "their large contribution to\\n\\t\\t\\t global disease burden, increasing trends, and variable patterns across countries at the same level of development.\\n\\t\\t\\t GBD 2016 findings show that, while it has huge potential to improve health, risk modification has played a relatively\\n\\t\\t\\t small part in the past decade.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 317, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5eb7149f-7f21-4510-ba90-775b0fa540b6": {"__data__": {"id_": "5eb7149f-7f21-4510-ba90-775b0fa540b6", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "63660035-afd4-49a0-9037-19a6544bd45e", "node_type": "4", "metadata": {}, "hash": "d835e78b6a9a3a278d28af811f73e8f2553784d47485d3dd5319830960a1cbd8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Background\\nMobile technologies could be a powerful media for providing individual level support to health care consumers. We conducted a systematic review to assess the effectiveness of mobile technology interventions delivered to health care consumers.\\nMethods and Findings\\nWe searched for all controlled trials of mobile technology-based health interventions delivered to health care consumers using MEDLINE, EMBASE, PsycINFO, Global Health, Web of Science, Cochrane Library, UK NHS HTA (Jan 1990\u2013Sept 2010). Two authors extracted data on allocation concealment, allocation sequence, blinding, completeness of follow-up, and measures of effect. We calculated effect estimates and used random effects meta-analysis. We identified 75 trials. Fifty-nine trials investigated the use of mobile technologies to improve disease management and 26 trials investigated their use to change health behaviours. Nearly all trials were conducted in high-income countries. Four trials had a low risk of bias. Two trials of disease management had low risk of bias; in one, antiretroviral (ART)", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1083, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "be6176ac-c745-4347-9617-1cbf126a057b": {"__data__": {"id_": "be6176ac-c745-4347-9617-1cbf126a057b", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0a8d410b-a401-4b20-9834-167ece82cebc", "node_type": "4", "metadata": {}, "hash": "b8cacdc4774cfe4cdccabf05a42e91036cdb42434591c4138c85d4bccf1caf5f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "adherence, use of text messages reduced high viral load (>400 copies), with a relative risk (RR) of 0.85 (95% CI 0.72\u20130.99), but no statistically significant benefit on mortality (RR 0.79 [95% CI 0.47\u20131.32]). In a second, a PDA based intervention increased scores for perceived self care agency in lung transplant patients. Two trials of health behaviour management had low risk of bias. The pooled effect of text messaging smoking cessation support on biochemically verified smoking cessation was (RR 2.16 [95% CI 1.77\u20132.62]). Interventions for other conditions showed suggestive benefits in some cases, but the results were not consistent. No evidence of publication bias was demonstrated on visual or statistical examination of the funnel plots for either disease management or health behaviours. To address the limitation of the older search, we also reviewed more recent literature.\\nConclusions\\nText messaging interventions increased adherence to ART and smoking cessation and should be considered for inclusion", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1018, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b9173d09-2e52-40e5-91db-5373d7282fa7": {"__data__": {"id_": "b9173d09-2e52-40e5-91db-5373d7282fa7", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4afe26dd-d1bc-4481-9832-6cc606f78391", "node_type": "4", "metadata": {}, "hash": "66fb98805b15b3eb1469c44045b1de10aadb80ebd9241bc0b9c454b49ba4f298", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "in services. Although there is suggestive evidence of benefit in some other areas, high quality adequately powered trials of optimised interventions are required to evaluate effects on objective outcomes.\\n Please see later in the article for the Editors' Summary\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 265, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e9a12905-d0e8-4eff-8dec-f59247d836ff": {"__data__": {"id_": "e9a12905-d0e8-4eff-8dec-f59247d836ff", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "80fca3a0-4dfa-411f-bbb6-cd2f625818fb", "node_type": "4", "metadata": {}, "hash": "d9e5304c87e2faf71ed14f849c6f743bc6a893bf9c9bc4222085fd3a24fc2267", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ASSOCIATED WITH Cerebral Visual Impairment and Intellectual Disability (ortholog); INTERACTS WITH (S)-nicotine (ortholog); 2,3,7,8-tetrachlorodibenzodioxine (ortholog); 4,4'-diaminodiphenylmethane (ortholog)\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 211, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b349cd00-567e-458b-9647-49be010a141f": {"__data__": {"id_": "b349cd00-567e-458b-9647-49be010a141f", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a0272232-94c8-4747-a942-8e0ee6b62ccc", "node_type": "4", "metadata": {}, "hash": "07512fe53c7d176a7e944b0d329bd228af68643beffe7f684a95926c1ff5a644", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Objective\\nPreterm birth is the main reason for neonatal deaths worldwide. We investigate whether maternal gut microbiota may play a previously overlooked role.\\nMethods\\nThe Norwegian Microbiota Study (NoMIC) is a case control study on preterm birth (<259 days of gestation, calculated primarily based on the last menstrual period), including two consecutively born term infants per infant born prematurely. Eligible mothers were fluent in Norwegian and recruited from the maternity ward at a county hospital in Eastern Norway in the period 2002\u20132005. Fecal samples were collected at day 4 postpartum, and analyzed using 16S ribosomal RNA gene sequencing. We used samples from 121 mothers giving birth vaginally. Measures of alpha diversity (Shannon, Phylogenetic Diversity and Observed Operational Taxonomic Units) and microbiome composition were combined with information from the Medical Birth Registry, pregnancy journals, and questionnaires.\\nResults\\nThe association between maternal gut diversity and preterm delivery was examined using logistic regression. One IQR increase in Shannon", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1095, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ef573871-63fb-403a-b264-c3945ce09bc6": {"__data__": {"id_": "ef573871-63fb-403a-b264-c3945ce09bc6", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "aed126ba-a4fa-4b2c-b857-3ceed2e5e5ec", "node_type": "4", "metadata": {}, "hash": "742d9321eed05657d65f3a2d1b185d320063b3f39c9d67bcfdc38962040d41af", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "diversity was significantly associated with 38% lower odds of spontaneous preterm birth, (95% confident interval (CI): 1%, 61%), and the association was stronger when adjusting for maternal age, marital status, ethnicity, parity, BMI, education, antibiotic use, pets in the household, income and smoking (48% lower odds, 95% CI: 4.2%, 72%). Mothers delivering prematurely also had lower abundance of OTUs belonging to Bifidobacterium and Streptococcus, and of the Clostridiales order.\\nConclusion\\nAnalysis of maternal gut microbiota using next-generation sequencing shows that low gut diversity, with a distinct microbial composition, is associated with spontaneous preterm delivery.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 686, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4671e372-227e-479d-8cde-8b57125af1d1": {"__data__": {"id_": "4671e372-227e-479d-8cde-8b57125af1d1", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c38c3e6f-110e-41f5-98df-fdf5a2d1eac5", "node_type": "4", "metadata": {}, "hash": "768f5da7c9291650cda1c8eb1b00f6f9b64de009d5d504340b66c6287cb37778", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"INVOLVED IN defense response to bacterium (inferred); innate immune response (inferred); ASSOCIATED WITH Neurodevelopmental Disorders (ortholog); FOUND IN extracellular region (inferred); INTERACTS WITH bisphenol A; (S)-nicotine (ortholog); 2,3,7,8-tetrachlorodibenzodioxine (ortholog)\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 289, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4363af07-5f74-4fd3-9a26-570ec037f2ee": {"__data__": {"id_": "4363af07-5f74-4fd3-9a26-570ec037f2ee", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "92371eb7-be2c-4107-b52d-c3f5a2366918", "node_type": "4", "metadata": {}, "hash": "f69d08c30dfbe3099916e59f6351bdbaa86d8936e54510dd03f382295db72022", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"ENCODES a protein that exhibits metal ion binding (inferred); nucleic acid binding (inferred); zinc ion binding (inferred); FOUND IN cytosol (ortholog); nucleolus (ortholog); INTERACTS WITH (S)-nicotine; 2,3,7,8-tetrachlorodibenzodioxine; aflatoxin B1\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 255, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5e180497-af30-4447-931d-becd277c1a3a": {"__data__": {"id_": "5e180497-af30-4447-931d-becd277c1a3a", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f18e879a-48ae-44ce-a2af-543a3b26af23", "node_type": "4", "metadata": {}, "hash": "288c26c9458adf8dd9879c160a5060f7119112c069af245be649ea01f9e88612", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Predicted to have G-protein beta-subunit binding activity. Predicted to be involved in G protein-coupled receptor signaling pathway. Predicted to localize to the G-protein beta/gamma-subunit complex and heterotrimeric G-protein complex. ENCODES a protein that exhibits GTPase activity (inferred); INVOLVED IN signal transduction (inferred); PARTICIPATES IN glutamate signaling pathway; FOUND IN plasma membrane (inferred); INTERACTS WITH (S)-nicotine; aflatoxin B1; antirheumatic drug\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 488, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d84495bd-3662-4e8b-a1ce-8b29093c0d8f": {"__data__": {"id_": "d84495bd-3662-4e8b-a1ce-8b29093c0d8f", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "46bf9d8e-8bb7-46de-bafb-d855f44a4096", "node_type": "4", "metadata": {}, "hash": "0913cab85f7312bf6c6f62139449b41e2554fe5f6eb45262136bdad68244c8da", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Non-typeable Haemophilus influenzae (NTHi) is a key pathogen in COPD, being associated with airway inflammation and risk of exacerbation. Why some patients are susceptible to colonisation is not understood. We hypothesised that this susceptibility may be due to a deficiency in mucosal humoral immunity. The aim of our study (NCT01701869) was to quantify the amount and specificity of antibodies against NTHi in the lungs and the associated risk of infection and inflammation in health and COPD. Phlebotomy, sputum induction and bronchoscopy were performed on 24 mild-to-moderate COPD patients and 8 age and smoking-matched controls. BAL (Bronchoalveolar lavage) total IgG1, IgG2, IgG3, IgM and IgA concentrations were significantly increased in COPD patients compared to controls. NTHi was detected in the lungs of 7 of the COPD patients (NTHi+ve\u201429%) and these patients had a higher median number of previous exacerbations than NTHi-ve patients as well as evidence of increased systemic inflammation. When", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1009, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dd372a99-ae25-4c7c-913b-646eefe2b45a": {"__data__": {"id_": "dd372a99-ae25-4c7c-913b-646eefe2b45a", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e4e387fe-96f4-49ce-9a6e-9f9e5fc4e0e1", "node_type": "4", "metadata": {}, "hash": "15697f20de9febc64a0a96d5a857363e2ab6a0c864f3452617e6a280356df496", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "comparing NTHi+ve versus NTHi-ve patients we observed a decrease in the amount of both total IgG1 (p = 0.0068) and NTHi-specific IgG1 (p = 0.0433) in the BAL of NTHi+ve patients, but no differences in total IgA or IgM. We observed no evidence of decreased IgG1 in the serum of NTHi+ve patients, suggesting this phenomenon is restricted to the airway. Furthermore, the NTHi+ve patients had significantly greater levels of IL-1\u03b2 (p = 0.0003), in BAL than NTHi-ve COPD patients.This study indicates that the presence of NTHi is associated with reduced levels and function of IgG1 in the airway of NTHi-colonised COPD patients. This decrease in total and NTHI-specific IgG1 was associated with greater systemic and airway inflammation and a history of more frequent exacerbations and may explain the susceptibility of some COPD patients to the impacts of NTHi.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 858, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a70266cd-acd6-429f-a95a-b77e844728e6": {"__data__": {"id_": "a70266cd-acd6-429f-a95a-b77e844728e6", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c3239938-f567-4119-8c83-bd0950043528", "node_type": "4", "metadata": {}, "hash": "d78b8c42cfbd2b612b4f5a090399fc6ff0d7755bd46eb9c61b96c6c22bf7863d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "[\"Viral-bacterial co-infections are associated with severe exacerbations of COPD. Epithelial antimicrobial peptides, including human \u03b2-defensin-2 (HBD-2), are integral to innate host defenses. In this study, we examined how co-infection of airway epithelial cells with rhinovirus and Pseudomonas aeruginosa modulates HBD-2 expression, and whether these responses are attenuated by cigarette smoke and in epithelial cells obtained by bronchial brushings from smokers with normal lung function or from COPD patients. When human airway epithelial cells from normal lungs were infected with rhinovirus, Pseudomonas aeruginosa, or the combination, co-infection with rhinovirus and bacteria resulted in synergistic induction of HBD-2 (p<0.05). The combination of virus and flagellin replicated this synergistic increase (p<0.05), and synergy was not seen using a flagella-deficient mutant Pseudomonas (p<0.05). The effects of Pseudomonas aeruginosa were mediated via interactions of flagellin with TLR5. The effects of HRV-16 depended upon viral replication but did not appear to be mediated via the intracellular", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1107, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3f40c087-0f2c-4052-b5ed-df4ee4f04dda": {"__data__": {"id_": "3f40c087-0f2c-4052-b5ed-df4ee4f04dda", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d199bceb-69c6-40f1-8c0c-f38cedd54f65", "node_type": "4", "metadata": {}, "hash": "84191d2d7c13147b66f48224d18799459ed95cae320bc1370f55f384bdac4629", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "RNA helicases, retinoic acid-inducible gene-I or melanoma differentiation-associated gene-5. Cigarette smoke extract significantly decreased HBD-2 production in response to co-infection. Attenuated production was also observed following co-infection of cells obtained from healthy smokers or COPD patients compared to healthy controls (p<0.05). We conclude that co-exposure to HRV-16 and Pseudomonas aeruginosa induces synergistic production of HBD-2 from epithelial cells and that this synergistic induction of HBD-2 is reduced in COPD patients. This may contribute to the more severe exacerbations these patients experience in response to viral-bacterial co-infections.\"]", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 673, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/ref_doc_info": {"379a7942-d426-4d60-a7cd-d4ce1dafcd41": {"node_ids": ["1f8a1b4a-bb8e-4a09-a7d6-c24fb34821e1"], "metadata": {}}, "b459346f-b701-49a9-ba4c-becbd4f6eef8": {"node_ids": ["566ff003-e9c6-421e-ab87-7b01605105d7"], "metadata": {}}, "2b70ecd1-b2bd-4753-b17c-f1426aca769d": {"node_ids": ["7d3e29da-89a0-4112-84a9-6c2ed1139717"], "metadata": {}}, "a189ad72-2a7e-43a4-9ab0-2310630984ab": {"node_ids": ["4a3ad329-9f70-4f8a-83cf-befe036a4a46"], "metadata": {}}, "8a1c836b-d65d-440a-8f99-22f1348c46b8": {"node_ids": ["5b962085-5130-4e8d-a4b0-140ed4db2936"], "metadata": {}}, "52b88f37-a79a-4ab6-84ba-e169a631b807": {"node_ids": ["ad6d9332-1f2f-44fd-8d75-ac976234fb18"], "metadata": {}}, "1e0ce963-25d3-4f79-8244-c2d6ac4b0195": {"node_ids": ["9c122296-d245-4c54-a42b-82163b1b8b93"], "metadata": {}}, "eb101c39-4be2-463b-bc2c-43fddb5d4189": {"node_ids": ["9935b7e9-6b2a-4f59-b82f-6aab5d775c93"], "metadata": {}}, "f7b640a4-06ea-4603-a995-3e1d426bdb29": {"node_ids": ["d0da3769-8197-454d-b6a3-1603946c9630"], "metadata": {}}, "525d253d-709c-4846-85ed-050168e9b353": {"node_ids": ["2db3b3fa-1725-46e9-9363-ff0184a237f9"], "metadata": {}}, "b88ac031-8b9a-40ee-8b4f-d46457879876": {"node_ids": ["58479ebc-7ccc-4212-a2b7-4e3dc92639e8"], "metadata": {}}, "cc6a8cb5-a714-4c19-854d-448b4e7facc1": {"node_ids": ["ff389915-24b9-4cc0-b702-9350b6bb9a79"], "metadata": {}}, "f78d6af1-a210-4614-8709-dadee648219e": {"node_ids": ["5149fba1-44cb-462e-bca7-d2d8d7c480e5"], "metadata": {}}, "68f5f365-9515-440f-99d0-d0a7d7f744f4": {"node_ids": ["d18b1e00-33ad-4c77-bd3e-9f68b5e8e5a8"], "metadata": {}}, "75f276b1-dc73-448d-b3df-f2949ebae042": {"node_ids": ["a5059593-19bf-440d-bc3e-c4302034d845"], "metadata": {}}, "9ebcde90-cd9f-4577-b66e-0492708e0483": {"node_ids": ["e4b2144b-4676-477c-9fcf-3f16ca35a752"], "metadata": {}}, "10c759b9-62c2-403f-b566-b50f9b521dd0": {"node_ids": ["a20600b6-e2cf-4dcc-94b1-41b1f8d0a1ae"], "metadata": {}}, "1b520a3e-d95e-473e-bd63-7e54520282b1": {"node_ids": ["fff52cff-78ea-4507-b56e-49e61f916d47"], "metadata": {}}, "c2bb20df-19eb-479c-8207-5232fd6face1": {"node_ids": ["38d5ffb7-2cb5-4f2d-a464-a530361e5bbb"], "metadata": {}}, "ee375edc-6a5b-44ba-9063-9fadb3fb3854": {"node_ids": ["8c25c87c-a435-4f15-873e-4d44247c4968"], "metadata": {}}, "32a92ec0-51a7-4325-afbf-7964259752a1": {"node_ids": ["2d43d55d-ca09-41fc-bb78-8f71dd775f55"], "metadata": {}}, "f4c367a5-8e03-4981-8d10-e577efa17c6d": {"node_ids": ["f9b94697-bc8e-45da-b9d2-53a784e4c144"], "metadata": {}}, "8f65c141-4a20-4b4d-b945-bfe013e121f2": {"node_ids": ["3455efc6-2d7c-4c93-a8a4-f0b1bfbc7b90"], "metadata": {}}, "07d95561-d14c-499b-966d-0d03d75e7d29": {"node_ids": ["2276bb05-eed2-490d-beb4-a0d51870171f"], "metadata": {}}, "85c9ae0e-3931-457f-9c7c-3e9a99677b3f": {"node_ids": ["d15d7fa3-aadc-4c30-ac00-9de947585d0e"], "metadata": {}}, "86a20e20-d169-455e-9851-3c0fd1e349f7": {"node_ids": ["3720fd6b-6b28-4a36-a1cf-44ab1ecb8181"], "metadata": {}}, "33edf4a4-5010-4d67-a387-7db9d38877c0": {"node_ids": ["0008012f-39e0-42e2-8cad-790093e25627"], "metadata": {}}, "51184805-c391-407c-b8ab-43ef952e090e": {"node_ids": ["d6d140b3-c392-4c2d-b42e-303a1a2e1dd5"], "metadata": {}}, "515b3860-179f-4d79-aa5f-c7af37b77a69": {"node_ids": ["e729a7a7-b3f7-4c66-bc90-6679cda7deb7"], "metadata": {}}, "825bc117-ff0a-42be-9d9f-35c8bbac21ba": {"node_ids": ["90f9a33b-6e32-40c6-ad67-a095f234e930"], "metadata": {}}, "07754aab-2daf-46b0-9cfb-75a40022faf2": {"node_ids": ["b0fbef65-ecf3-4a97-9aac-cea5a5f485a2"], "metadata": {}}, "480f028e-4b50-4e77-9fab-3ca65be81ffe": {"node_ids": ["716ee2d5-bec8-4526-b174-f26e717eae35"], "metadata": {}}, "f986cd49-070b-4d42-ac9b-cd894a9d834e": {"node_ids": ["b59af04f-a898-4d4c-a853-6f07430c8625"], "metadata": {}}, "ddc54b96-3ab6-4f99-8e78-a6437c6d1877": {"node_ids": ["108eb530-ce90-406e-a77b-b42a08425f15"], "metadata": {}}, "09a23a89-d6e1-4b37-9770-96bbe87560b8": {"node_ids": ["63464ff0-9287-4d99-b86f-1aa7f1731ad2"], "metadata": {}}, "bab6e1af-7013-497b-984a-62fbc119b94b": {"node_ids": ["f23c8bb0-7732-42c2-94ce-bec01b30ab41"], "metadata": {}}, "fad18478-0f39-4f3c-a26c-6e7417c6bc30": {"node_ids": ["4b33678c-d8c5-4162-ac14-b3ced1d0cce8"], "metadata": {}}, "bca5d914-8363-4775-aa79-0dbcf482ef98": {"node_ids": ["cca9fd02-6789-4746-abab-e1a79d930cc7"], "metadata": {}}, "0718ecd1-aaa4-4496-b175-b691c8ec8833": {"node_ids": ["e64b2b10-79c9-4498-b5fc-b5257c6102ef"], "metadata": {}}, "0a8126e6-ef15-4069-9014-9377e77bd8db": {"node_ids": ["8b179273-dbca-4a7b-bd6f-b91ea559c337"], "metadata": {}}, "8e6ff787-6761-4b6a-b47e-a803bb22633f": {"node_ids": ["366c7e0d-b386-459b-8f55-22adb0967d30"], "metadata": {}}, "a2fb9a64-965e-44fc-b82c-f8bb58aed32c": {"node_ids": ["75c59af7-e82e-437a-9c8a-bc6809ece297"], "metadata": {}}, "626fd3ce-52cf-46df-bd55-c7979f3387b5": {"node_ids": ["c3ebf273-b0c3-4eb0-833f-305089a7abf5"], "metadata": {}}, "69c3357b-940f-4cf6-98b1-0ffc12680b76": {"node_ids": ["94b717cf-0e7a-4af1-b02e-5d896e9ee8ff"], "metadata": {}}, "d00cd52c-48dc-458b-9461-63bed191d1e9": {"node_ids": ["a321271c-f947-439f-92ee-2f91623939d3"], "metadata": {}}, "fb58b84b-0bc3-47a0-b8be-951afaf2f4d6": {"node_ids": ["a1aafc7c-c342-4a1c-8039-9e471d8caaae"], "metadata": {}}, "f76c1a1d-6034-4baa-9a23-b67b5202f40e": {"node_ids": ["bfbf5b89-632f-4a9d-a345-fe1a37b01dbf"], "metadata": {}}, "3efc6a40-a67d-4302-8a96-b5b6fc28415b": {"node_ids": ["9c434ab9-2e36-49dc-ab3d-ade85752eabe"], "metadata": {}}, "64402d25-895d-45d9-9695-c3c7ae6162fe": {"node_ids": ["4a09fc11-5a5d-45e4-a172-cee625ba4634"], "metadata": {}}, "3ce22e43-adb2-43cb-bd8a-67ffc57caefc": {"node_ids": ["d2c45121-255c-4a44-86f2-956425f569a4"], "metadata": {}}, "ce3cb6ab-8fbe-4b47-99d2-8c5ba4e19a7d": {"node_ids": ["cb1f88e3-072f-428a-877e-df0892599412"], "metadata": {}}, "5f30f38c-7a63-4baf-89f3-6b75728d8ea4": {"node_ids": ["c458f722-7c61-4af9-b72a-95e11791d4aa"], "metadata": {}}, "92e960f6-092d-479b-aa01-55aec4130a70": {"node_ids": ["cededcaa-1d1b-4458-ae93-b826a08204b2"], "metadata": {}}, "a8c94450-1b41-4e27-b5da-497cc15d07fc": {"node_ids": ["497c5bb0-0c83-4751-95ab-56103e2df367"], "metadata": {}}, "f6ae0ff4-9c4f-4870-952a-efb73935703d": {"node_ids": ["0c755704-3f45-4582-8f2d-9b09fd836ae6"], "metadata": {}}, "9b6e527d-f83b-4095-848f-44ea0803e244": {"node_ids": ["76eee6fc-ca4b-4b6b-ae7f-e076b2edc5b6"], "metadata": {}}, "575791d3-021b-4569-9de9-d1b0afdcdf0d": {"node_ids": ["6bc1f391-39aa-4fc8-b3dc-07271ddec689"], "metadata": {}}, "af5a7a84-a0ba-4ac0-8ea8-36502e81ccbe": {"node_ids": ["367b9265-b730-44a3-9149-8b4661346844"], "metadata": {}}, "045b78b1-9c84-4a29-8bf7-64c94e60e9be": {"node_ids": ["adac1fbd-1731-43ee-81b7-883f8f6d7b16"], "metadata": {}}, "3c86e01d-19ee-4dde-bd3d-07fda3d2da7a": {"node_ids": ["7ad3c40f-09b7-4de9-b8e3-90ae703d13e8"], "metadata": {}}, "7570211d-85c8-49da-99e1-dc3f037d83f4": {"node_ids": ["93cbeb7b-8704-426a-89b2-c998e3a7632b"], "metadata": {}}, "6bfa7dcd-dc94-4b23-9257-141945c3cb48": {"node_ids": ["82e83df3-1a02-41f0-8348-0f2521b29db2"], "metadata": {}}, "463d7c25-6d92-4c5c-8eee-9cc27fb0bd6e": {"node_ids": ["d774b46c-11d7-4ecb-850f-8d88a02d8b57"], "metadata": {}}, "a6692b3f-56dd-4ef4-844c-31bac5698b03": {"node_ids": ["ce86acb4-4045-4b65-9c14-2d460df29c9e"], "metadata": {}}, "5ccfc505-d8c2-43ad-817e-e36d7300b179": {"node_ids": ["0a569a32-4af5-468b-9e3f-8bdc251131e3"], "metadata": {}}, "9a4862c0-2c36-41df-8ad4-981878441600": {"node_ids": ["079244c3-02cc-46fa-93aa-afbe0af52da7"], "metadata": {}}, "0c072d0a-6a98-4e1a-a7cd-79b9c71589ad": {"node_ids": ["a184d45a-d98f-4f7e-9938-9e41199ecaaf"], "metadata": {}}, "6fd149d8-f196-4892-abae-fe698f01916a": {"node_ids": ["e49072e5-34cd-4298-b0a8-abdf58853728"], "metadata": {}}, "ed943ff1-0464-4398-bf7a-0d8fbbeca0d3": {"node_ids": ["95ccbbc2-0be8-4b3f-93c1-db7fa562be06"], "metadata": {}}, "c2a9410d-1021-4b1d-8e37-76dccb721b03": {"node_ids": ["cb1a559b-f2dd-4eae-8171-484d192a10ba"], "metadata": {}}, "c7c7a898-be6e-4468-8923-0f77a490f21b": {"node_ids": ["1d7b12b3-027e-4681-b378-f42125d6e048"], "metadata": {}}, "e6bdfe42-9113-47df-b54e-67412f7c081b": {"node_ids": ["eceb91ce-d5d1-4271-8c60-be68a824cad1"], "metadata": {}}, "d7e62501-a8c4-4a6e-a73e-25a3c43e674e": {"node_ids": ["58732b24-265a-4cdd-91ca-9f56d5b78e9e"], "metadata": {}}, "d7bcf9d5-4a1a-4699-ba6c-bee2cdc9f4f2": {"node_ids": ["b276f0a5-a5cd-4b54-b22e-ce4bc66ffbd2"], "metadata": {}}, "b6293498-5a80-4cd9-867a-a96a606120c7": {"node_ids": ["a17965d4-a342-4265-976f-b35b406e58f4"], "metadata": {}}, "86c69809-b181-46bf-97fb-cd56e19ce40a": {"node_ids": ["ea739c0a-c962-407a-9659-53d0ffb709c5"], "metadata": {}}, "ffc793a0-da1d-4e88-a2a1-51691fcf509a": {"node_ids": ["e36e1915-4716-4ec7-8263-9389511f550b"], "metadata": {}}, "463571c9-bab0-44a7-a4c9-9782851b527a": {"node_ids": ["264dc903-d521-4dd9-8ad0-6d7be3478de9"], "metadata": {}}, "63660035-afd4-49a0-9037-19a6544bd45e": {"node_ids": ["5eb7149f-7f21-4510-ba90-775b0fa540b6"], "metadata": {}}, "0a8d410b-a401-4b20-9834-167ece82cebc": {"node_ids": ["be6176ac-c745-4347-9617-1cbf126a057b"], "metadata": {}}, "4afe26dd-d1bc-4481-9832-6cc606f78391": {"node_ids": ["b9173d09-2e52-40e5-91db-5373d7282fa7"], "metadata": {}}, "80fca3a0-4dfa-411f-bbb6-cd2f625818fb": {"node_ids": ["e9a12905-d0e8-4eff-8dec-f59247d836ff"], "metadata": {}}, "a0272232-94c8-4747-a942-8e0ee6b62ccc": {"node_ids": ["b349cd00-567e-458b-9647-49be010a141f"], "metadata": {}}, "aed126ba-a4fa-4b2c-b857-3ceed2e5e5ec": {"node_ids": ["ef573871-63fb-403a-b264-c3945ce09bc6"], "metadata": {}}, "c38c3e6f-110e-41f5-98df-fdf5a2d1eac5": {"node_ids": ["4671e372-227e-479d-8cde-8b57125af1d1"], "metadata": {}}, "92371eb7-be2c-4107-b52d-c3f5a2366918": {"node_ids": ["4363af07-5f74-4fd3-9a26-570ec037f2ee"], "metadata": {}}, "f18e879a-48ae-44ce-a2af-543a3b26af23": {"node_ids": ["5e180497-af30-4447-931d-becd277c1a3a"], "metadata": {}}, "46bf9d8e-8bb7-46de-bafb-d855f44a4096": {"node_ids": ["d84495bd-3662-4e8b-a1ce-8b29093c0d8f"], "metadata": {}}, "e4e387fe-96f4-49ce-9a6e-9f9e5fc4e0e1": {"node_ids": ["dd372a99-ae25-4c7c-913b-646eefe2b45a"], "metadata": {}}, "c3239938-f567-4119-8c83-bd0950043528": {"node_ids": ["a70266cd-acd6-429f-a95a-b77e844728e6"], "metadata": {}}, "d199bceb-69c6-40f1-8c0c-f38cedd54f65": {"node_ids": ["3f40c087-0f2c-4052-b5ed-df4ee4f04dda"], "metadata": {}}}}